Литература с 2000 по 2019 год

А

Абдуалиева Г.М., Макимбетов Э.К. Диагностика и лечение ретинобластомы // Вестник КРСУ. 2013. Т. 13, № 1. С. 91-94.
http://arch.kyrlibnet.kg/uploads/KRSUABDUALIEVAG.M.2013-1.pdf

Аксель Е.М., Горбачева И.А. Заболеваемость детей злокачественными новообразованиями и смертность от них в России и странах СНГ // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2007 Т. 18, № 2. C. 136-154.
https://cyberleninka.ru/article/n/zabolevaemost-detey-zlokachestvennymi-novoobrazovaniyami-i-smertnost-ot-nih-v-rossii-i-stranah-sng-1/viewer

Алексеева Е.А., Бабенко О.В., Козлова В.М., Ушакова Т.Л., Казубская Т.П., Саакян С.В., Танас А.С., Залетаев Д.В., Стрельников В.В. Эффект родительского происхождения мутации в гене rb1 при наследственной ретинобластоме с низкой пенетрантностью. Медицинская генетика. 2019. Т. 18. № 8 (205). С. 21-28.
https://doi.org/10.25557/2073-7998.2019.08.21-28
https://www.medgen-journal.ru/jour/article/view/714

Алексеева Е.А., Бабенко О.В., Козлова В.М., Ушакова Т.Л., Саакян С.В., Танас А.С., Немцова М.В., Стрельников В.В., Залетаев Д.В. Результаты использования новой медицинской технологии комплексной ДНК-диагностики ретинобластомы. Медицинская генетика. 2017. Т. 16.№ 10. С. 41-46.
https://www.medgen-journal.ru/jour/article/view/336/252

Б

Бабенко О.В., Бровкина А.Ф., Залетаев Д.В., Козлова В.М., Саакян С.В., Немцова М.В. Молекулярная диагностика ретинобластомы. Первый опыт в России // Вестник офтальмологии. 2002. № 1. С. 28-31.
http://www.fesmu.ru/elib/Article.aspx?id=70636

Бабенко О.В., Землякова В.В., Немцова М.В., Саакян С.В., Бровкина А.Ф., Козлова В.М., Залетаев Д.В. Молекулярная патология при ретинобластоме. Молекулярная медицина. 2003. № 2. С. 48.

Бегимкулова А.С. Анализ заболеваемости и результаты лечения ретинобластомы // Тихоокеанский медицинский журн. 2011. № 3. C. 39-40.
https://cyberleninka.ru/article/n/analiz-zabolevaemosti-i-rezultaty-lecheniya-retinoblastomy/viewer

Белкина Б.М. Ретинобластома. / Дурнов Л.А., Голдобенко Г.В.. Учебник «Детская онкология». М.: Медицина, 2002. Глава 18. С. 413-438.

Белкина Б.М., Поляков В.Г., Дурнов Л.А., Глеков И.В., Голдобенко Г.В. Результаты комбинированной лучевой и химиотерапии при местнораспространенной ретинобластоме. Детская хирургия. 2001. №5. С. 11-13.
http://www.fesmu.ru/elib/Article.aspx?id=65029

Белоусова Е.И., Матинян Н.В., Мартынов Л.А., Летягин И.А., Ушакова Т.Л., Поляков В.Г. Эффективность и безопасность ретробульбарной блокады ропивакаином при проведении селективной интраартериальной химиотерапии у детей с ретинобластомой. Вестник интенсивной терапии имени А.И. Салтанова. 2019. №3. С. 58-65.
DOI: 10.21320/1818-474X-2019-3-58-64
http://intensive-care.ru/effektivnost-i-bezopasnost-retrobulbarnoj-blokady-ropivakainom-pri-provedenii-selektivnoj-intraarterialnoj-himioterapii-u-detej-s-retinoblastomoj/

Боброва Н. Ф., Сорочинская Т. А. Атипичная клиника ретинобластомы. Российская педиатрическая офтальмология. 2009. № 4. С. 25-28.
https://www.medlit.ru/j/rpo/rpo090425.htm

Боброва Н.Ф., Сорочинская Т.А., Локальная и системная полихимиотерапия ретинобластомы. Офтальмология. Восточная Европа. 2012. № 3(14). С. 57-66.
https://elibrary.ru/download/elibrary_17955015_22018716.pdf

Боброва Н.Ф., Сорочинская Т.А., Тронина С.А., Левицкий И.М. Лейкокория при ретинобластоме различных стадий и локализаций. Российская детская офтальмология № 2. 2015.
https://eyepress.ru/article.aspx?18071

Бровкина А.Ф. Лучевая терапия в лечении опухолей органа зрения. РМЖ «Клиническая Офтальмология» 2003; 1:15. https://www.rmj.ru/articles/oftalmologiya/Luchevaya_terapiya_v_lechenii_opuholey_organa_zreniya/

Бровкина А.Ф. Офтальмоонкология: руководство для врачей. М.: Медицина, 2002. 424 с.
https://medknigaservis.ru/product/oftalmoonkologiya-rukovodstvo/

Бровкина А.Ф. Ретинобластома // Наследственные и врожденные заболевания сетчатки и зрительного нерва / под ред. А. М. Шамшиновой. М.: Медицина, 2001. 528 с.

Бровкина А.Ф. Современная концепция лечения ретинобластомы. Вестник офтальмологии. 2005. № 2. С. 48-51.
https://elibrary.ru/download/elibrary_24080691_10544869.pdf

Бровкина А.Ф., Панова И.Е., Саакян С.В. Офтальмоонкология: новое за последние два десятилетия. Вестник офтальмологии. 2014. Т. 130. № 6. С. 13-19.
Булгакова Е.С., Кривовяз О.С., Яровой А.А., Голубева О.В., Ушакова Т.Л., Поляков В.Г., Горовцова О.В. Семилетний опыт лечения детей с ретинобластомой в ФГБУ «МНТК "Микрохирургия глаза" им. акад. С.Н. Федорова». Современные технологии в офтальмологии. 2015.№ 2. С. 188-190.
https://eyepress.ru/article.aspx?18054

Булгакова Е.С., Яровой А.А., Ушакова Т.Л. и др. Эффективность брахитерапии при лечении ретинобластомы // XI Всероссийская научно-практическая конференция с международным участием. Фёдоровские чтения. М., 2013. С. 150-151.
DOI: 10.18786/2072-0505-2018-46-2-132-136
https://eyepress.ru/article.aspx?20340

В

Вериго Е.Н., Гундорова Р.А., Пряхина И.А. Психологические аспекты в реабилитации больных с анофтальмом. Офтальмология. 2012. 9(3): 81-84.
https://www.ophthalmojournal.com/opht/article/view/161/153

Вериго Е.Н., Макаров П.В. Протезирование в комплексной медико-социальной реабилитации пациентов при офтальмопатологии. Медико-социальная экспертиза и реабилитация.2016. 4:182-185.
https://cyberleninka.ru/article/n/protezirovanie-v-kompleksnoy-mediko-sotsialnoy-reabilitatsii-patsientov-pri-oftalmopatologii/viewer

Вериго Е.Н., Пряхина И.А., Садовская Е.П., Лаврентьева Н.В. Характеристика глазных протезов и показания к их применению. Глаз, 2011; 3: 79: 9-14.

Вериго Е. Н., Садовская Е. П., Катаев М. Г., Лаврентьева Н. В. // Проблемы реабилитации детей с анофтальмом // Российская педиатрическая офтальмология. 2010. № 3. С. 32-35.

Вериго Е.Н., Садовская Е.П., Неверовский А.Е. Медико-социальная реабилитация больных с анофтальмом. Реабилитология. М., 2003; 403-405.

Вериго Е.Н., Тучин В.А., Пряхина И.А. Исторические аспекты глазного протезирования. В помощь практическому врачу. Вестник офтальмологии. 2012. №5.
https://www.mediasphera.ru/issues/vestnik-oftalmologii/2012/5/downloads/ru/030042-465X2012511

Вериго Е.Н., Филатова И.А., Ткаченко О.Н. Возможности эктопротезирования в реабилитации пациентов с патологией орбиты. Вестник офтальмологии. 2017;133(5): 64-68.
DOI: 10.17116/oftalma2017133564-68
https://www.mediasphera.ru/issues/vestnik-oftalmologii/2017/5/10042465X2017051064

Г

Гарькавцева Р.Ф., Казубская Т.П., Любченко Л.Н. и др. Наследственный рак: идентификация, генетическая гетерогенность, медико-генетическое консультирование // Вестник РАМН. 2001. С. 27-33.

Горовцова О.В., Ушакова Т.Л., Поляков В.Г.Современные возможности органосохраняющего лечения детей с интраокулярной ретинобластомой. Онкопедиатрия. 2018. 5(3). С. 175-187.
DOI: 10.15690/onco.v5i3.1935
https://www.oncopediatria.ru/jour/article/view/226/240

Гундорова Р.А., Быков В.П., Вериго Е.Н., Харлампиди М.П. Глазопротезная помощь: проблемы и пути решения в современных условиях. Окулист, 2004; 12: 18-19.

Гундорова Р.А., Вериго Е.Н., Тучин А.В. и др. Анализ состояния глазопротезной помощи на территории России. Вестник офтальмологии, 2011; 127: 5: 61-64.

Гундорова Р.А., Вериго Е.Н., Харлампиди М.П, Садовская Е.П. Вопросы эпидемиологии и реабилитации лиц с анофтальмом на территории РФ. Вестник офтальмологии. 2007. № 3. С. 42-46.


Д

Делягин В.М., Мельникова М.Б., Герберг А.М. Клинико-радиологические аспекты ретинобластомы // Медицинский журнал «SonAce-International». 2006. № 15. С. 42-47.
https://www.medison.ru/si/art245.htm

Долгушин Б.И., Ушакова Т.Л., Погребняков И.В., Трофимов И.А., Кукушкин А.В., Виршке Э.Р., Горовцова О.В., Серов Ю.А., Яровой А.А., Саакян С.В., Поляков В.Г. Роль селективной интраартериальной и интравитреальной химиотерапии в органосохраняющем лечении детей с ретинобластомой. ЭНИ Забайкальский медицинский вестник. 2018. №1. С. 7-24.
http://zabmedvestnik.ru/journal/2018/1/2.pdf

Дурнов Л.А. Руководство по детской онкологии. М.: Миклош, 2003. 504 с.
https://www.mmbook.ru/catalog/pediatrija/100545-detail

Дурнов Л.А., Голдобенко Г.В. Детская онкология. М.: Медицина, 2002. 608 с.

Е

Еремин В.П., Дудкина Е.Ю. Атипичный случай ретинобластомы глаза // Современные технологии в офтальмологии. 2014. № 2. С. 158-159.
https://eyepress.ru/article.aspx?13942

Ж

Жаруа А.В. Комбинированное лечение далекозашедших и резистентных форм ретинобластомы: автореф. дис… канд. мед.наук. М., 2013. 24 с.
http://medical-diss.com/medicina/kombinirovannoe-lechenie-dalekozashedshih-i-rezistentnyh-form-retinoblastomy

З

Заева Г.Е, Валиев Т.Т., Гавриленко Т.Ф. и др. Отдаленные последствия терапии злокачественных опухолей у детей: 35-летний опыт клинических наблюдений. Современная онкология. 2016. Vol.18, №1. P.55-60.
https://www.elibrary.ru/item.asp?id=26099452

Залетаев Д.В. Современная молекулярная генетика в офтальмологии // Наследственные и врожденные заболевания сетчатки и зрительного нерва / под ред. А. М. Шамшиновой. М.: Медицина, 2001. 528 с.

Заридзе Д.Г. Эпидемиология и профилактика рака // Вестник РАМН. 2001. № 9. С. 6-14.

Злокачественные новообразования в России: 1993-2013, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой, ответственный за издание проф. В.В. Старинский. МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России http://www.oncology.ru/service/statistics/malignant_tumors/

Злокачественные новообразования в России в 2011 году (заболеваемость и смертность) / под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2013.

Злокачественные новообразования в России в 2012 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014.
http://www.oncology.ru/service/statistics/malignant_tumors/2012.pdf

Зуева М.В., Саакян С.В. Электрофизиологические исследования ретинальной функции после системной и суперселективной внутриартериальной химиотерапии в лечении ретинобластомы. Вестник офтальмологии. 2015. Т.131. №5. С. 111-114.
10.17116/oftalma20151315111-114.
https://www.mediasphera.ru/issues/vestnik-oftalmologii/2015/5/120042-465X20150516

Зуева М.В., Цапенко И.В., Саакян С.В., Пантелеева О.Г., Жаруа А.А., Орловская Л.С. Вызванные потенциалы сетчатки и зрительной коры у детей с далеко зашедшей и резистентной ретинобластомой после неоадъювантной полихимиотерапии и суперселективной внутриартериальной химиотерапии. Вестник офтальмологии. 2014. Т.130. №5. С. 22-29.
https://www.mediasphera.ru/issues/vestnik-oftalmologii/2014/5/030042-465X201454

И

Исламов З.С. Изучение распространенности ретинобластомы в Узбекистане. Онкопедиатрия. 2014.
https://cyberleninka.ru/article/n/izuchenie-rasprostranennosti-retinoblastomy-v-uzbekistane

Исламов З.С., Усманов Р.Х. Клиника и диагностика ретинобластомы. Практическая медицина. 2016.
https://cyberleninka.ru/article/n/klinika-i-diagnostika-retinoblastomy

К

Казубская Т.П., Козлова Т.П., Ушакова Т.Л.. Алексеева Е.А.. Стрельников В.В., Яровая В.А., Трофимов Е.И., Михайлова С.Н., Любченко Л.Н. Изучение пенетрантности и фенотипа ретинобластомы. Вопросы онкологии.2018. том 64, №2, С. 234-241.
https://elibrary.ru/download/elibrary_34858096_41117074.pdf

Казубская Т.П., Козлова В.М., Ушакова Т.Л., Горовцова О.В., Серов Ю.А., Михайлова С.Н., Стрельников В.В., Трофимов Е.И. Молекулярная диагностика ретинобластомы в клинической практике. Справочник заведующего КДЛ. 2018. №5. С. 48-63.
https://e.zavkdl.ru/641044

Катаргина Л.А., Арестова Н.Н., Михайлова Л.А. Достижения детской офтальмологии в Российской Федерации за 10 лет // Российская педиатрическая офтальмология. 2018. Vol. 13, № 2. P. 62–66.
DOI: 10.18821/1993-1859-2018-13-2-62-66
https://elibrary.ru/item.asp?id=35449385

Качанов Д.Ю., Абдуллаев Р. Т., Шаманская Т. В., Инюшкина Е. В., Добреньков К. В. Генетические синдромы у детей с онкологическими заболеваниями. Онкогематология, 2010.
https://cyberleninka.ru/article/n/geneticheskie-sindromy-u-detey-so-zlokachestvennymi-novoobrazovaniyami

Качанов Д.Ю., Крючко Н.В., Абдуллаев Р.Т. и др. Медико-частотные характеристики злокачественных новообразований у детей первого года жизни в Московской области (популяционное исследование). Онкогематология. 2010. № 2. C. 55-62.
https://cyberleninka.ru/article/n/mediko-chastotnye-harakteristiki-zlokachestvennyh-novoobrazovaniy-u-detey-pervogo-goda-zhizni-na-territorii-moskovskoy-oblasti/viewer

Качанов Д.Ю., Тамазян Г.В., Крючко Н.В. и др. Злокачественные новообразования у детей первого года жизни (обзор литературы). Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2010. Т. 9, № 1. C. 14-21.
https://elibrary.ru/download/elibrary_15581598_46424844.pdf

Козина Е.В., Ворошилова Н.А., Браун В.Н., Голобардова Н.Ю. Случай неонатальной бинокулярной ретинобластомы. Медицинский вестник Башкортостана. 2018.
https://cyberleninka.ru/article/n/sluchay-neonatalnoy-binokulyarnoy-retinoblastomy

Козлова В.М., Алексеева К.А., Бабенко О.В., Ушакова Т.Л., Горовцова О.В., Казубская Т.П., Любченко Л.Н., Поляков В.Г. Результаты молекулярно-генетических исследований пациентов с ретинобластомой. Онкопедиатрия. 2015. Т. 2. № 3. С. 281.
https://cyberleninka.ru/article/n/rezultaty-molekulyarno-geneticheskih-issledovaniy-patsientov-s-retinoblastomoy/viewer

Козлова В.М., Казубская Т.П., Соколова И.Н. и др. Ретинобластома: диагностика и генетическое консультирование. Онкопедиатрия. 2015. № 2 (1). С. 30-38.
https://www.oncopediatria.ru/jour/article/view/26/30

Козлова В.М., Ушакова Т.Л., Поляков В.Г., Вассерман Н.Н., Поляков А.В., Гарькавцева Р.Ф. Дифференциальный диагноз ретинобластомы и наследственной псевдоглиомы сетчатки глаз (клинический случай). Детская онкология. 2004. № 3-4. С. 52-53.
https://elibrary.ru/download/elibrary_9125573_32921273.pdf

Копнин Б. П. Опухолевые супрессоры и мутаторные гены // Канцерогенез; под ред. Д. Г. Заридзе. Москва: Научный мир, 2000. С. 75–93.
https://gigabaza.ru/doc/75489-pall.html

Кривовяз О.С., Булгакова Е.С., Яровой А.А. Способ потенцирования транспупиллярной лазерной термотерапии при ретинобластоме. Современные технологии в офтальмологии, № 3. 2015.
https://eyepress.ru/article.aspx?17879

Кривовяз О.С., Яровой А.А., Булгакова Е.С., Ушакова Т.Л., Горовцова О.В. Тяжелые формы ретинобластомы: эффективность локальной терапии в системе органосохраняющего лечения. Актуальные проблемы офтальмологии. 2013.
https://eyepress.ru/article.aspx?12071

Кривовяз О.С., Яровой А.А., Ушакова Т.Л., Поляков В.Г., Булгакова Е.С., Голубева О.В., Горовцова О.В. Витреоретинальные осложнения после комбинированного органосохраняющего лечения ретинобластомы. Современные технологии в офтальмологии. 2014.№ 1. С. 67-68.
https://eyepress.ru/0001710/vitreo14_press.pdf

Кричевская Г.И., Слепова О.С., Саакян С.В., Мякошина Е.Б., Денисова Е.В. К вопросу о роли инфекций в патогенезе ретинобластомы. Российский офтальмологический журнал. 2013. Т. 6, № 2. С. 37-40.
https://roj.igb.ru/jour/manager/files/archive/%D0%A0%D0%9E%D0%96_2_2013.pdf

Кулева С.А., Иванова С.В., Садовникова Н.Н. и др. Ретинобластома: клиника, диагностика и лечение: учебно-методическое пособие для обучающихся в системе высшего и дополнительного профессионального образования. СПб.: Фалкон Принт; 2019.

Кулева С. А., Иванова С. В., Садовникова Н. Н., Бржеский В. В., Комиссаров М. И., Чистякова М. Н., Артемьева А. С., Хохлова А. В., Детков В. Ю., Щеголева Н. А., Баранов А. В., Семиглазова Т. Ю., Балдуева И. А., Звягинцева Д. А., Рязанкина А. А., Рогачев М. В., Беляев А. М. Ретинобластома: клиника, диагностика и лечение. Учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России. СПб., 2019. https://www.niioncologii.ru/education/education/training/training_manuals_2023/Кулева_С_А_Ретинобластома_2019.pdf

Кулева С.А., Колыгин Б.А. Вторые опухоли, возникающие после терапии злокачественных опухолей у детей // Вопросы онкологии. 2012. № 5. С. 606-615.
https://elibrary.ru/item.asp?id=17989411

А

Abdolahi A., Van Wijngaarden E., McClean M.D. et al. A case-control study of paternal occupational exposures and the risk of childhood sporadic bilateral retinoblastoma // Occupational and environmental medicine. 2013. Vol.70. P. 372-379.
DOI: 10.1136/oemed-2012-101062
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666318/

Abouzeid H., Moeckli R., Gaillard M.C., Beck-Popovic M. et all. (106)Ruthenium Brachytherapy for Retinoblastoma. Int J Radiat Oncol 2008; 71(3):821–8.
doi: 10.1016/j.ijrobp.2007.11.004
https://pubmed.ncbi.nlm.nih.gov/18207660/

Abramson D.H. Chemosurgery for Retinoblastoma. What We Know After 5 Year // Archives of ophthalmology. 2011. Vol. 129. N 11. P. 1492-1494.
DOI:10.1001/archophthalmol.2011.354
https://www.researchgate.net/publication/51799071_Chemosurgery_for_Retinoblastoma_What_We_Know_After_5_Years

Abramson D.H. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture // Investigative Ophthalmology & Visual Science. 2005. Vol. 46. N 8. Р. 2683-2691.
DOI: 10.1167/iovs.04-1462
https://iovs.arvojournals.org/article.aspx?articleid=2182695

Abramson D.H. Retinoblastoma: saving life with vision // Annual Review of Medicine. 2014. Vol. 65. Р. 171-184.
DOI: 10.1146/annurev-med-061312-123455
https://www.annualreviews.org/doi/abs/10.1146/annurev-med-061312-123455

Abramson D.H. Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: 'chemosurgery' the first Stallard lecture. British Journal of Ophthalmology. 2010; 94(4): 396-399.
DOI: 10.1136/ bjo.2009.174268.
https://www.ncbi.nlm.nih.gov/pubmed/20424209

Abramson D.H. et al. Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma. Ophthalmic Genet. Taylor and Francis Ltd, 2018. Vol. 39, № 3. P. 353–356.
Doi 10.1080/13816810.2018.1443343

Abramson D.H. et al. Systemic carboplatin for retinoblastoma: Change in tumour size over time. Br. J. Ophthalmol. 2005. Vol. 89, № 12. P. 1616–1619.
DOI: 10.1136/bjo.2005.072033
https://pubmed.ncbi.nlm.nih.gov/16299142/

Abramson D.H., Daniels A., Marr B. et al. Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. PLoS One. 2016. Vol.11, № 1. e0146582.
DOI: 10.1371/journal.pone.0146582.
https://pubmed.ncbi.nlm.nih.gov/26756643/

Abramson D.H., Dunkel I.J., Brodie S.E. et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008; 115(8): 1398-1404
DOI: 10.1016/j.ophtha.2007.12.014.
https://www.ncbi.nlm.nih.gov/pubmed/18342944

Abramson D.H., Dunkel I.J., Brodie S.E. et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010. Vol.128, №3. P. 370 - 2.
DOI: 10.1001/archophthalmol.2010.7
https://pubmed.ncbi.nlm.nih.gov/20212212/
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425226

Abramson D.H., Dunkel I.J., Brodie S.E., Marr B., Gobin Y.P. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010 Aug;117(8):1623-9.
doi: 10.1016/j.ophtha.2009.12.030.
https://pubmed.ncbi.nlm.nih.gov/20381868/

Abramson D.H., Du T.T., Beaverson K.L. (Neonatal) retinoblastoma in the first month of life. Arch Ophthalmol. 2002 Jun;120(6):738-42. PMID: 12049578.
doi: 10.1001/archopht.120.6.738

Abramson D.H., Fabius A.W., Francis J.H., Marr B.P., Dunkel I.J., Brodie S.E., Escuder A., Gobin Y.P. Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. Ophthalmic Genet. 2017 Jan-Feb;38(1):16-21. Epub 2017 Jan 17.
doi: 10.1080/13816810.2016.1244695.
https://pubmed.ncbi.nlm.nih.gov/28095092/

Abramson D.H., Francis J.H., Gobin Y.P. What's new in intra-arterial chemotherapy for retinoblastoma? International Ophthalmology Clinics. 2019. 59:87–94.
DOI: 10.1097/IIO.0000000000000266
https://insights.ovid.com/crossref?an=00004397-201905920-00008

Abramson D.H., Marr B.P., Brodie S.E., et al. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five-year review. PLoS One. 2012; 7 (4): e34120. doi: 10.1371/journal.pone.0034120
https://pubmed.ncbi.nlm.nih.gov/22545080/

Abramson D.H., Marr B.P, Dunkel I.J. et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2 year results. British Journal of Ophthalmology. 2012; 96(4): 499–502.
DOI: 10.1136/ bjophthalmol-2011-300498.
https://bjo.bmj.com/content/96/4/499

Abramson D.H., Marr B.P., Francis J.H., et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (Tandem Therapy). PLoS One. 2016; 11 (6): e0156806.
doi: 10.1371/journal.pone.0156806
https://pubmed.ncbi.nlm.nih.gov/27258771/

Abramson D.H., Melson M.R., Dunkel I.J., Frank C.M. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001. Vol.108, №10. P.1868–76.
DOI: 10.1016/s0161-6420(01)00713-8.
https://pubmed.ncbi.nlm.nih.gov/11581064/

Abramson D.H., Melson M.R., Servodidio C. Visual fields in retinoblastoma survivors. Arch Ophthalmol. 2004. Vol.122, №9. P.1324–30.
DOI: 10.1001/archopht.122.9.1324
https://pubmed.ncbi.nlm.nih.gov/15364711/

Abramson D.H., Schefler A.C. Update on retinoblastoma. Retina. 2004; 24 (6): 828–48. doi: 10.1097/00006982-200412000-00002
https://pubmed.ncbi.nlm.nih.gov/15579980/

Abramson D.H., Shields C.L., Jabbour P., Teixeira L.F., Fonseca J.RF., Marques M.C.P., Munier F.L., Puccinelli F., Hadjistilianou T., Bracco S., Chantada G.L., Ceciliano A., Gobin Y.P. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. International Journal of Retina and Vitreous. 2017;3:40.
DOI: 10.1186/s40942-017-0093-8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651563/

Abramson D.H., Shields C.L., Munier F.L., Chantada G.L. Treatment of retinoblastoma in 2015: Agreement and disagreement. JAMA Ophthalmology. 2015. 133:1341–7.
DOI: 10.1001/jamaophthalmol.2015.3108
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2442777

Acquaviva A., Ciccolallo L., Rondelli R. et al. Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of Italian retinoblastoma registry.// Oncogene, 2006, 25, pp.5350-5357.
DOI: 10.1038/sj.onc.1209786
https://www.nature.com/articles/1209786

Aerts I., Lumbroso-Le Villars M., Rouic L., Gauthier et al. Retinoblastoma. Orphanet Journal of Rare Diseases. 2006 Aug 25;1:31.
DOI: 10.1186/1750-1172-1-31
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1586012/

Aerts I., Pacquement H., Doz F. et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur. J. Cancer. 2004. Vol.40. P.1522–1529
DOI: 10.1016/j.ejca.2004.03.023
https://pubmed.ncbi.nlm.nih.gov/15196536/

Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31(11):1458-1463
https://www.ncbi.nlm.nih.gov/pubmed/23460706

AlAli A., Kletke S., Gallie B., Lam W.C. Retinoblastoma for Pediatric Ophthalmologists. Asia Pac J Ophthalmol (Phila). 2018 May-Jun;7(3):160-168.
DOI: 10.22608/APO.201870
https://journals.lww.com/apjoo/Fulltext/2018/05000/Retinoblastoma_for_Pediatric_Ophthalmologists.7.aspx

Aldiri I., Xu B., Wang L., Chen X., Hiler D., etc. St. Jude children's research hospital – Washington university pediatric cancer genome project The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis. 2017, Neuron 94, 550–568.
https://doi.org/10.1016/j.neuron.2017.04.022 e10

Alejandra Valenzuela, Helen S. L. Chan, Elise Héon, Brenda L. Gallie. A Language for Retinoblastoma: Guidelines and Standard Operating Procedures. Pediatric Retina. 2010.
DOI: 10.1007/978-3-642-12041-1_9
https://link.springer.com/chapter/10.1007/978-3-642-12041-1_9

Ali A.A.E., Elsheikh S.M.A., Elhaj A. et al. Clinical Presentation and Outcome of Retinoblastoma among Children Treated at the National Cancer Institute (NCI) in Gezira, Sudan: A single institution experience // Ophthalmic Genetics. 2011. Vol. 32. N 2. P. 122-125.
DOI: 10.3109/13816810.2010.546822
https://www.ncbi.nlm.nih.gov/pubmed/21366428

Ali M.J., Parsam V.L., Honavar S.G., Kannabiran C., Vemuganti G.K., Reddy V.A. RB1 gene mutations in retinoblastoma and its clinical correlation. Saudi J Ophthalmol 2010;24(4):119–23.
doi: 10.1016/j.sjopt.2010.05.003.
https://pubmed.ncbi.nlm.nih.gov/23960888/

Almarzouki H.S., Bababeygy S.R., Berry J.L., Murphree A.L. Optic nerve length in enucleated specimens of retinoblastoma eyes: a surgical approach to retinoblastoma. J AAPOS 2011;15(1):e11.
doi: 10.1016/j.jaapos.2011.01.043.

Ammanuel S., Alexander M.D., Damato B., Cooke D.L., Halbach V.V., Amans M.R. et al. Improved procedural safety following protocol changes for selective ophthalmic arterial infusion of chemotherapy for treatment of ocular retinoblastoma. Interventional Neuroradiology.2018;24:345–50.
DOI: 10.1177/1591019918755088
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967188/

Anagnoste S.R., Scott I.U., Murray T.G., Kramer D., Toledano S. Rhegmatogenous retinal detachment in retinoblastoma patients undergoing chemoreduction and cryotherapy. Am J Ophthalmol. 2000 Jun;129(6):817-9.
doi: 10.1016/s0002-9394(00)00407-4.
https://pubmed.ncbi.nlm.nih.gov/10927003/

Anand B., Ramesh C., Appaji L., Kumari B.S., Shenoy A.M., Nanjundappa, Jayshree R.S., Kumar R.V. Prevalence of high-risk human papillomavirus genotypes in retinoblastoma. Br J Ophthal. 2011; 95(7):1014–1018.
DOI: 10.1136/bjo.2010.199802
https://www.ncbi.nlm.nih.gov/pubmed/21436174

Ancona-Lezama D., Dalvin L.A., Lucio-Alvarez J.A., Jabbour P., Shields C.L. Ophthalmic vascular events after intra-arterial chemotherapy for retinoblastoma: Real-World Comparison Between Primary and Secondary Treatments. Retina. 2019 Dec;39(12):2264-2272.
doi: 10.1097/IAE.0000000000002315.
https://pubmed.ncbi.nlm.nih.gov/30204728/

Antoneli C.B., Ribeiro K.C., Steinhorst F. et al. Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AS Camargo Hospital // Brazil. Journal of pediatric hematology/oncology. 2006. Vol. 28. P. 342-345.
DOI: 10.1097/00043426-200606000-00004
https://www.ncbi.nlm.nih.gov/pubmed/16794500

Araki Y., Matsuyama Y., Kobayashi Y. et al. Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. Japanese Journal of Clinical Oncology. 2011. Vol.41, №3. P.373-379.
DOI: 10.1093/jjco/hyq201. Epub 2010 Nov 4
https://pubmed.ncbi.nlm.nih.gov/21051531/

Asadi Amoli F., Piri N., Shams H. Etiologies of pseudoretinoblastomas in histopathologic speciemens of enucleated or exenterated eyes with clinical diagnosis of retinoblastoma. Acta medica Iranica. March 2005. 43(2):105-109
https://www.researchgate.net/publication/216427719_Etiologies_of_pseudoretinoblastomas_in_histopathologic_speciemens_of_enucleated_or_exenterated_eyes_with_clinical_diagnosis_of_retinoblastoma

Aung L., Chan Y.H., Yeoh E.J., Tan P.L., Quah T.C. Retinoblastoma: a recent experience at the National University Hospital, Singapore. Ann Acad Med Singapore. 2009; 38(8):693-69819736573
http://www.annals.edu.sg/pdf/38VolNo8Aug2009/V38N8...

Aziz H.A., Kim J., Munier F., Berry J. Acute hemorrhagic retinopathy following intravitreal melphalan injection for retinoblastoma: a report of two cases and technical modifications to enhance the prevention of retinal toxicity. Ocular Oncology and Pathology. 2016. Vol.3, №1.
DOI: 10.1159/000448718
https://pubmed.ncbi.nlm.nih.gov/28275601/

B

Babenko O.V., Saakian S.V., Brovkina A.F., Kozlova V.M., Strel'nikov V.V., Zaletaev D.V., Nemtsova M.V. Spectrum and frequencies of RB1 gene structural defects in retinoblastoma. Молекулярная биология. 2002. Т. 36. № 4. С. 623-629.

Babenko O.V., Zemliakova V.V., Saakian S.V., Brovkina A.F., Strel'nikov V.V., Zaletaev D.V., Nemtsova M.V. RB1 and CDKN2A functional defects resulting in retinoblastoma. Молекулярная биология. 2002. Т. 36. № 5. С. 777-783.

Badhu B., Sah S.P., Thakur S.K.D. et al. Clinical presentation of retinoblastoma in Eastern // Clinical & Experimental Ophthalmology. 2005. Vol. 33. N 4. P. 386-389.
DOI: 10.1111/j.1442-9071.2005.01010.x
https://www.ncbi.nlm.nih.gov/pubmed/16033351

Bahritdinova F., Islamov Z. Clinical Characteristics and Differential Diagnosis of Retinoblastoma // Medical and Health Science Journal. 2012. Vol. 12. P. 2-6.
https://elibrary.ru/download/elibrary_18056996_31142861.pdf

Bai S., Ren R., Shi J. et al. Retinoblastoma in the Beijing Tongren Hospital from 1957 to 2006: clinic pathological findings // British Journal of Ophthalmology. 2011. Vol. 95. N 8. P. 1072-1076.
DOI: 10.1136/bjo.2010.181396
https://www.ncbi.nlm.nih.gov/pubmed/20644215

Baker, Meredith S.; McConnell, Lindsay K.; Kleinberg, Teri T.; Shriver, Erin M.; Bilyk, Jurij R.; Allen, Richard C. Orbital sarcomas in retinoblastoma patients. recommendations for screening and treatment guidelines. Current Opinion in Ophthalmology. 2016. 27(5): 443-448 DOI: 10.1097/ICU.0000000000000295.
https://europepmc.org/article/med/27213925

Bakhshi S. et al. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: Correlation with IRSS staging. J. Pediatr. Hematol. Oncol. J Pediatr Hematol Oncol, 2011. Vol. 33, № 5.
DOI: 10.1097/MPH.0b013e3182103f5c
https://pubmed.ncbi.nlm.nih.gov/21364467/

Balderrama J., Leal-Leal C.A., Alvis-Miranda H. et al. Intra-arterial chemotherapy for retinoblastoma: a practical review // Romanian Neurosurgery. 2013. Vol.20. N 4. P. 326-332.
DOI: 10.2478/romneu-2013-0016
https://cyberleninka.org/article/n/1408940

Balmer А., Munier F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma // Clinical Ophthalmology. 2007. Vol.1. N 4. P. 431-439.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704541/

Balmer A., Zografos L., Munier F. Diagnosis and current management of retinoblastoma // Oncogene. 2006. Vol. 25. P. 5341-5349.
DOI: 10.1038/sj.onc.1209622
https://www.nature.com/articles/1209622

Batra A., Kumari M., Paul R. et al. Quality of life assessment in retinoblastoma: a cross-sectional study of 122 survivors from India. Pediatric Blood & Cancer. 2016. Vol. 63, №2
DOI: 10.1002/pbc.25781
https://pubmed.ncbi.nlm.nih.gov/26488435/

Bekc M.N., Balmer A., Dessing C. et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J. Clin. Oncol. 2000. Vol. 18, № 15. P.2881-2887
DOI: 10.1200/jco.2000.18.15.2881

Bellaton E., Bertozzi A.I., Behar C. et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. British Journal of Ophthalmology. 2003. Vol.87. P.327-329.
DOI: doi: 10.1136/bjo.87.3.327.
https://pubmed.ncbi.nlm.nih.gov/12598448/

Bellerive C., Singh A.D. Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma. Ocul Oncol Pathol. 2017;4(3):157–160.
DOI: 10.1159/000481312
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939713/

Berman Е. L., Donaldson C.E., Giblin M. et al. Outcomes in retinoblastoma, 1974-2005: The Children's Hospital, Westmead // Clinical and Experimenal Ophthalmology. 2007. Vol.35. N 1. P. 5-12.
DOI: 10.1111/j.1442-9071.2006.01386.x
https://www.researchgate.net/publication/6504023_Outcomes_in_retinoblastoma_19742005_The_Children's_Hospital_Westmead

Berry J.L., Biegel J.A., Slavotinek A., Tirnauer J.S., Armsby C., Shah S. Gene test interpretation: RB1. Up to date. Oct 2021.
https://www.wolterskluwer.com/en/solutions/uptodate/

Berry J.L, Jubran R., Kim J.W., Wong K., Bababeygy S.R., Almarzouki H., Lee T.C., Murphree A.L. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013 Apr;60(4):688-93. Erratum in: Pediatr Blood Cancer. 2014 Jun;61(6):1147. Dosage error in article text. PMID: 22997170.
doi: 10.1002/pbc.24303

Berry J.L., Kogachi K., Murphree A.L., Jubran R., Kim J.W. A Review of Recurrent Retinoblastoma: Children's Hospital Los Angeles Classification and Treatment Guidelines. Int Ophthalmol Clin. 2019 Spring;59(2): 65-75.
DOI: 10.1097/IIO.0000000000000269
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676476/

Berry J.L., Lee R., Patel L., Le B.H.A, O'Fee J., Jubran R., Kim J.W. Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma. Ocul Oncol Pathol. 2019 Jun;5(4):238-244.
DOI: 10.1159/000493687
https://www.ncbi.nlm.nih.gov/pubmed/31367584

Berry J.L., Polski A., Cavenee W.K., Dryja T.P., Murphree A.L., Gallie B.L. The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene. Genes (Basel). 2019 Nov 1;10(11). pii: E879.
DOI: 10.3390/genes10110879
https://www.ncbi.nlm.nih.gov/pubmed/31683923

Berry J.L., Xu L., Polski A., Jubran R., Kuhn P., Kim J.W., Hicks J. Aqueous Humor Is Superior to Blood as a Liquid Biopsy for Retinoblastoma. Ophthalmology. 2019 Oct 31. pii: S0161-6420(19)32184-0.
DOI: 10.1016/j.ophtha.2019.10.026
https://www.aaojournal.org/article/S0161-6420(19)32184-0/fulltext

Berry J.L., Xu L., Kooi I., Murphree A.L., Prabakar R.K., etc. Genomic cfDNA analysis of aqueous humor in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retinoblastoma. 2018, Mol. Cancer Res. 16, 1701–1712.
https://doi.org/10.1158/1541-7786.MCR-18- 0369

Berry J.L., Xu, L., Murphree A.L., Krishnan S., Stachelek, K., etc. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. 2017, JAMA Ophthalmol 135, 1221-1230
https://doi.org/10.1001/ jamaophthalmol.2017.4097

Bertelli E., Leonini S., Galimberti D., Moretti S., Tinturini R., Hadjistilianou T. et al. Hemodynamic and anatomic varkaniations require an adaptable approach during intra-arterial chemotherapy for intraocular retinoblastoma: Alternative routes, strategies, and follow-up. American Journal of Neuroradiology. 2016.37:1289–95.
DOI: 10.3174/ajnr.A4741
http://www.ajnr.org/content/37/7/1289

Bhagat S.P., Bass J., White S. et al. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int. J. Pediatr. Otorhinolaryngol. 2010. Vol. 74, № 10. P. 1156-1163.
DOI: 10.1016/j.ijporl.2010.07.004
https://pubmed.ncbi.nlm.nih.gov/20667604/

Bhattacharya S., Beasley M., Dong Pang et al. Maternal and perinatal risk factors for childhood cancer: record linkage study // BMJ Open. 2014. N 4. - e003656.
DOI:10.1136/bmjopen-2013-003656.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902197/

Bianciotto C., Shields C.L., Iturralde J.C., Sarici A., Jabbour P., Shields J.A. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology. 2012. 119:843-9.
DOI: 10.1016/j.ophtha.2011.09.040
https://www.aaojournal.org/article/S0161-6420(11)00897-9/fulltext

Biewald E.M., Bornfeld N., Metz K.A., Schlüter S., Kiefer T., Radbruch A., Göricke S., Sirin S., Ketteler P., Bechrakis N.E. Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy. Br J Ophthalmol. 2019 Nov 1. pii: bjophthalmol-2019-315209.
DOI: 10.1136/bjophthalmol-2019-315209
https://www.ncbi.nlm.nih.gov/pubmed/31676593

Bonanomi М.Т., Almeida M.T., Cristofani L.M. Retinoblastoma: a three-year-study at a Brazilian medical school hospital // Clinics. 2009. Vol. 64. N 5. P. 427-434.
DOI: 10.1590/S1807-59322009000500010
https://www.researchgate.net/publication/26259356_Retinoblastoma_A_Three-Year-Study_at_a_Brazilian_Medical_School_Hospital

Bowman R.J, Mafwiri M., Luthert P. et al. Outcome of retinoblastoma in east Africa. Pediatr. Blood Cancer. 2008. Vol.50, №1. P.160 – 162.
DOI: 10.1002/pbc.21080
https://pubmed.ncbi.nlm.nih.gov/17120241/

Bracco S., Venturi C., Leonini S., Romano D.G., Cioni S., Vallone I.M., Gennari P., Hadjistilianou T., De Francesco S., Bertelli E. Transorbital anastomotic pathways between the external and internal carotid systems in children affected by intraocular retinoblastoma.
Surg Radiol Anat. 2016 Jan; 38(1):79-87.
DOI: 10.1007/s00276-015-1519-3.
https://www.ncbi.nlm.nih.gov/pubmed/26198114

Brennan R.C., Qaddoumi I., Billups C.A. et al. Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma // Br. J. Ophthalmol. 2015. № 10. P. 1366–1371.
DOI: 10.1136/ bjophthalmol-2014-306364
https://www.ncbi.nlm.nih.gov/pubmed/26198114

Brennan R.C., Qaddoumi I., Mao S., et al. Ocular salvage and vision preservation using a Topotecan-based regimen for advanced intraocular retinoblastoma. J. Clin. Oncol. 2017; 35(1): 72–7.
doi: 10.1200/JCO.2016.69.2996
https://pubmed.ncbi.nlm.nih.gov/28034080/

Bright C.J., Hawkins M.M., Winter D.L. et al. Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. JNCI: Journal of the National Cancer Institute. 2018. Vol.110, №6. P.649–660.
DOI: 10.1093/jnci/djx235
https://pubmed.ncbi.nlm.nih.gov/29165710/

Broaddus E., Торhаm A., Singh A. lncidence of retinoblastoma in the USA: 1975-2004 // British Journal of Ophthalmology. 2009. Vol. 93. P. 21-23.
DOI: 10.1136/bjo.2008.138750
https://bjo.bmj.com/content/93/1/21

Broaddus E., Topham A., Singh A.D. Survival with retinoblastoma in the USA: 1975-2004. Br. J. Ophthalmol. 2009. Vol.93, №1. P.24-27.
DOI: 10.1136/bjo.2008.143842
https://pubmed.ncbi.nlm.nih.gov/18718969/

Brodie S.E. et al. ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. Br. J. Ophthalmol. 2012. Vol. 96, № 6. P. 877–880.
DOI: 10.1136/bjophthalmol-2011-301248
https://pubmed.ncbi.nlm.nih.gov/22426950/

Brodie S.E., Munier F.L., Francis J.H., Marr B., Gobin Y.P., Abramson D.H. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Documenta Ophthalmologica. 2013. 126. 79-84.
DOI: 10.1007/s10633-012-9358-6
https://www.ncbi.nlm.nih.gov/pubmed/23143758

Bronkhorst A.J., Ungerer V., Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. 2019, Biomol Detect Quantif 17, 100087.
https://doi.org/10.1016/j.bdq.2019.100087

Buitrago E., Del Sole M.J., Torbidoni A., Fandino A., Asprea M., Croxatto J.O. et al. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Experimental Eye Research. 2013. 108:103-9.
DOI: 10.1016/j.exer.2013.01.002
https://www.ncbi.nlm.nih.gov/pubmed/23333535

Bunin G.R., Felice M. A., Davidson W. et al. Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutation // International Journal of Cancer. 2011. Vol. 128. N 10. P. 2393-2404.
DOI: 10.1002/ijc.25565
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124307/

Bunin G.R., Li Y., Ganguly A. et al. Parental nutrient intake and risk of retinoblastoma resulting from new germline RB1 mutation // Cancer Causes & Control. 2013. Vol. 24. P. 343-355.
DOI: 10.1007/s10552-012-0120-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557550/

Butros L.J., Abramson D.H., Dunkel I. J. Delayed Diagnosis of Retinoblastoma: Analysis of Degree, Cause, and Potential Consequences // Pediatrics. 2002. Vol. 109. N 3. P. 45.
DOI: 10.1542/peds.109.3.e45
https://www.ncbi.nlm.nih.gov/pubmed/11875173

C

Camp D.A., Dalvin L.A., Schwendeman R., Lim L.S., Shields C.L. Outcomes of neonatal retinoblastoma in pre-chemotherapy and chemotherapy eras. Indian J. Ophthalmol. 2019; 67: 1997–2004.
doi: 10.4103/ijo.ijo_634_19
https://pubmed.ncbi.nlm.nih.gov/31755437/

Canturk S., Qaddoumi I., Khetan V. et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators // British Journal of Ophthalmology. 2010. Vol. 94. P. 1432-1436.
DOI: 10.1136/bjo.2009.168062
https://www.ncbi.nlm.nih.gov/pubmed/20733021

Carreras E., Dufour C., Mohty M., Kroger N. Hematopoietic stem cell transplantation and cellular therapies. EBMT Handbook, 2019:117-130.

Cassoux N., Aerts I., Lumbroso-Le Rouic L., Freneaux P., Desjardins L. Eye salvage with combination of intravitreal and intracameral melphalan injection for recurrent retinoblastoma with anterior chamber involvement: report of a case. 2017, Ocul Oncol Pathol 3, 129–132.
https://doi.org/10.1159/000452305

Cassoux N., Lumbroso L., Levy-Gabriel C., et al. Retinoblastoma: update on current management. Asia Pac. J. Ophthalmol (Phila). 2017; 6 (3): 290–5.
doi:10.22608/APO.201778
https://pubmed.ncbi.nlm.nih.gov/28558178/

Chang C.Y., Chiou T.J., Hwang D. et al. Retinoblastoma in Taiwan: survival rate and prognostic factors. Jpn. J. Ophthalmol. 2006. Vol.50, №3. P. 242 –249.
DOI: 10.1007/s10384-005-0320-y.
https://pubmed.ncbi.nlm.nih.gov/16767380/

Chan M.P., Hungerford J.L., Kingston J.E., Plowman P.N. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol 2009;93(7):891–4.
doi :10.1136/bjo.2007.129981.
https://pubmed.ncbi.nlm.nih.gov/19329423/

Chantada G., Doz F., Antoneli C.B., Grundy R., Stannard F.F.C., Dunkel I.J. et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006;47(6):801–5.
doi: 10.1002/pbc.20606.
https://pubmed.ncbi.nlm.nih.gov/16358310/

Chantada G., Schaiquevich P. Management of retinoblastoma in children: current status. Paediatr Drugs 2015;17(3):185–98.
doi: 10.1007/s40272-015-0121-9.
https://pubmed.ncbi.nlm.nih.gov/25742925/

Chantada G.L. Retinoblastoma: lessons and challenges from developing countries // Ophthalmic Genetics. 2011. Vol. 32. P. 196-203.
DOI: 10.3109/13816810.2011.592173
https://www.ncbi.nlm.nih.gov/pubmed/21770696

Chantada G.L., Dunkel I.J., de Davila M.T., Abramson D.H. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? British Journal of Ophthalmology. 2004;88(8):1069–1073.
DOI: 10.1136/ bjo.2003.037044.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772257/

Chantada G.L., Dunkel I.J., Qaddoumi I. et al. Familial Retinoblastoma in Developing Countries // Pediatric Blood & Cancer. 2009. Vol. 53. P. 338-342.
DOI: 10.1002/pbc.21970
https://www.ncbi.nlm.nih.gov/pubmed/19434730

Chantada G.L., Fandino A.C., Raslawski E.C., et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatric Blood & Cancer. 2005;44(5):455–460.
DOI: 10.1002/pbc.20259.
https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.20259

Chantada G.L., Guitter M.R., Fandiño A.C. et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer 2009;52(2):218–22.
doi: 10.1002/pbc.21735.
https://pubmed.ncbi.nlm.nih.gov/18937327/

Chantada G.L., Leal-Leal C.A., Dunkel I.J. Metastatic retinoblastoma. In: Ramasubramanian A, Shields C.L., editors. Retinoblastoma. New Delhi, India: Jaypee Brothers Medical Publishers; 2012. Pp. 186-90.
Chhablani J., Romanzo A., Balmer A., Pica A., Gaillard M.C., Cozza R., Moeckli R., Munier F.L. (106)Ruthenium brachytherapy for ciliary recurrence with supraciliary eff usion in retinoblastoma. Ophthalmic Genet 2010; 31(4):190–2.
doi: 10.3109/13816810.2010.499888
https://pubmed.ncbi.nlm.nih.gov/20809777/

Chawla B., Hasan F., Azad R., Seth R., Upadhyay A.D., Pathy S. et al. Clinical presentation and survival of retinoblastoma in Indian children. Br J Ophthalmol 2016;100:1728.
doi: 10.1136/bjophthalmol-2015-306672
https://pubmed.ncbi.nlm.nih.gov/26061162/

Chawla B., Jain A., Azad R. Conservative treatment modalities in retinoblastoma. Indian J Ophthalmol 2013;61(9):479–85.
doi: 10.4103/0301-4738.119424.
https://pubmed.ncbi.nlm.nih.gov/24104705/

Chawla B, Singh R. Recent advances and challenges in the management of retinoblastoma. Indian Journal of Ophthalmology. 2017;65(2): 133-9.
DOI: 10.4103/ijo.IJO_883_16
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381292/

Chemaitilly W., Mertens A.C., Mitby P. et al. Acute ovarian failure in the childhood cancer survivor study. J. of Clin. Endocrinol. and Metabol. 2006. Vol.91. P.1723-1728.
DOI: 10.1210/jc.2006-0020
https://pubmed.ncbi.nlm.nih.gov/16492690/

Chen M., Jiang H., Zhang J., Shen G., Jiang Y., Li H., Liu Z. Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: A retrospective study. Acta Ophthalmologica.2017; 95:613–8.
DOI: 10.1111/aos.13333
https://www.ncbi.nlm.nih.gov/pubmed/27874261

Chen X., Kunda P.E., Lin J., Zhou M., Huang J., Zhang H., Liu T. SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma. 2018, J. Cancer Res. Clin. Oncol. 144, 675-684.
https://doi.org/10.1007/s00432-018-2584-x

Chévez-Barrios P. et al. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study // J. Clin. Oncol. NLM (Medline), 2019. Vol. 37, № 31. P. 2883–2891.
DOI: 10.1200/JCO.18.01808
https://pubmed.ncbi.nlm.nih.gov/31539297/

Chhablani J., Romanzo A., Balmer A., Pica A., Gaillard M.C., Cozza R., Moeckli R., Munier F.L. (106)Ruthenium brachytherapy for ciliary recurrence with supraciliary eff usion in retinoblastoma. Ophthalmic Genet 2010; 31(4):190–2.
doi: 10.3109/13816810.2010.499888
https://pubmed.ncbi.nlm.nih.gov/20809777/

Chia-Yau Chang, Tzeon-Jye Chiou, Betau Hwang et al. Retinoblastoma in Taiwan: Survival Rate and Prognostic Factors // Japanese Journal of Ophthalmology. 2006. Vol. 50. P. 242–249.
DOI: 10.1007/s10384-005-0320-y
https://www.researchgate.net/publication/7016808_Retinoblastoma_in_Taiwan_Survival_Rate_and_Prognostic_Factors

Chin K., Margolin C.B., Finger P.T. Early ocular prosthesis insertion improves quality of life after enucleation. Optometry. 2006 Feb;77(2):71-5.
doi: 10.1016/j.optm.2005.12.012.
https://pubmed.ncbi.nlm.nih.gov/16476649/

Chintagumpala M., Chevez –Barrios P., Paysse E. et al. Retinoblastoma: review of current management // The Oncologist. 2007. Vol. 12. P. 1237-1246.
DOI: 10.1634/theoncologist.12-10-1237
https://www.ncbi.nlm.nih.gov/pubmed/17962617

Chodick G., Kleinerman R.A., Stovall M. et al. Risk of cataract extraction among adult retinoblastoma survivors. Arch Ophthalmol 2009;127:1500–1504.
DOI: 10.1001/archophthalmol.2009.271
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818500/

Choudhury M. et al. A Multidisciplinary Approach for Rehabilitation of Enucleated Sockets: Ocular Implants with Custom Ocular Prosthesis // Cureus, Inc., 2018.
DOI: 10.7759/cureus.2201
https://pubmed.ncbi.nlm.nih.gov/29666779/

Choy K.W., Pang C.P., Fan D.S.P., Lee T.C., Wang J.H., Abramson D.H., etc. 2004, Microsatellite instability and MLH1 promoter methylation in human retinoblastoma. Invest. Ophthalmol. Vis. Sci. 45, 3404.
https://doi.org/10.1167/iovs.03-1273

Choy K.W., Lee T.C., Cheung K.F., Fan D.S.P., Lo K.W., Beaverson K.L., Abramson D. H., etc. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. 2005. Neoplasia 7, 200-206.
https://doi.org/10.1593/neo.04565

Chung S.E., Sa H.S., Koo H.H. et al. Clinical manifestations and treatment of retinoblastoma in Korea // British Journal of Ophthalmology. 2008. Vol. 92. P. 1180-1184.
DOI: 10.1136/bjo.2008.140046
https://www.ncbi.nlm.nih.gov/pubmed/18650212

Corson T.W., Gallie B.L. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. 2007, Genes Chromosomes Cancer 46, 617-634.
https://doi.org/10.1002/gcc.20457

D

Dalvin L.A., Kumari M., Essuman V.A., Shohelly Shipa S., Ancona-Lezama D., Lucio-Alvarez J.A. et al. Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: Five years of experience. Ocular Oncology and Pathology.2019;5:139–46.
DOI: 10.1159/000491580
https://www.ncbi.nlm.nih.gov/pubmed/30976594

Daniels A.B., Mukai S. Modern surgical techniques in the management of retinoblastoma // Int. Ophthalmol. Clin. Lippincott Williams and Wilkins, 2017. Vol. 57, № 1. P. 195–218.
DOI: 10.1097/IIO.0000000000000151
https://pubmed.ncbi.nlm.nih.gov/27898624/

Darwich R., Ghazawi F.M., Rahme E., Alghazawi N., Burnier J.V., Sasseville D., Burnier M.N., Litvinov I.V. Retinoblastoma Incidence Trends in Canada: A National Comprehensive Population-Based Study. Journal of Pediatric Ophthalmology and Strabismus. 2019;56(2):124-130
https://doi.org/10.3928/01913913-20190128-02
https://www.healio.com/ophthalmology/journals/jpos...

Dean M., Bendfeldt G., Lou H. et al. Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala. Cancer Lett. 2014; 351(1):59-63
DOI: 10.1016/j.canlet.2014.04.023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490907/

Dehainault C., Golmard L., Millot G.A., Charpin A., Laug´e A., Tarabeux J., Aerts I., Cassoux N., etc. Mosaicism and prenatal diagnosis options: insights from retinoblastoma. 2017, Eur. J. Hum. Genet. 25, 381–383.
https://doi.org/10.1038/ejhg.2016.174

Demirci H., Shields C.L., Meadows A.T., Shields J.A. Long-term visual outcome following chemoreduction for retinoblastoma // Archieves of Ophthalmology. 2005. Vol. 123. P. 1525-1530.
DOI: 10.1001/archopht.123.11.1525
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/417335

Desjardins L., Chefchaouni M.C., Lumbroso L. et al. Functional results after treatment of retinoblastoma. J. AAPOS. 2002. Vol.6, №2. P.108–11.
DOI: 10.1067/mpa.2002.121451
https://pubmed.ncbi.nlm.nih.gov/11997807/

Dhar, S.U., Chintagumpala, M., Noll, C. et al, Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol. 2011;129:1428–1434
doi: 10.1001/archophthalmol.2011.292
https://jamanetwork.com/journals/jamaophthalmology...

Dillon A.B., Douglass A., Jabbour P., Shields C.L. Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome. Oman Journal of Ophthalmology. 2016. 9:164–6.
DOI: 10.4103/0974-620X.192278
https://www.ncbi.nlm.nih.gov/pubmed/27843232

Dimaras H., Corson T.W., Cobrinik D., White A., Zhao J., Munier F.L. et al. Retinoblastoma. Nat Rev Dis Prim 2015;1:15021.
doi: 10.1038/nrdp.2015.21.
https://pubmed.ncbi.nlm.nih.gov/27189421/

Dimaras H., Corson T.W., Cobrinik D., White A., Zhao J., Munier F.L., Abramson D. H., Shields C.L., Chantada G.L., Njuguna F., Gallie B.L. Retinoblastoma. 2015, Nat. Rev. Dis. Prim. 1, 15021
https://doi.org/10.1038/nrdp.2015.21

Dimaras H., Dimba E.A., Gallie B.L. Challenging the global retinoblastoma survival disparity through a collaborative research effort // British Journal of Ophthalmology. 2010. Vol. 94. N 11. P. 1415-1416.
DOI: 10.1136/bjo.2009.174136
https://www.researchgate.net/publication/45461224_Challenging_the_global_retinoblastoma_survival_disparity_through_a_collaborative_research_effort

Dimaras H., Kimani K., Dimba E.A.O., Gronsdahl P., White A., Chan H.S.L., Gallie B. L. Retinoblastoma. 2012, Lancet 379, 1436–1446.
https://doi.org/10.1016/S0140-6736(11)61137-9

Dommering C.J., Mol B.M., Moll A.C., Burton M., Cloos J., Dorsman J.C., MeijersHeijboer H., van der Hout A.H., 2014. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. J. Med. Genet. 51, 366–374.
https://doi.org/10.1136/jmedgenet-2014-102264

Dommering C.J., Henneman L., van der Hout A.H., Jonker M.A., Tops C.M.J., etc. Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in The Netherlands. 2017, Fam. Cancer 16, 271–277.
https://doi.org/10.1007/s10689-016-9943-z

Dunkel I.J., Jubran R.F., Gururangan S., Chantada G.L., Finlay J.L., Goldman S. et al. Trilateral retinoblastoma: Potentially curable with intensive chemotherapy. Pediatric Blood & Cancer. 2010. 54:384–7.
DOI: 10.1002/pbc.22336
https://www.ncbi.nlm.nih.gov/pubmed/19908299

Dunkel I.J., Chan H.S., Jubran R., Chantada G.L., Goldman S., Chintagumpala M. et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatric Blood & Cancer.2010. 55:149–52
DOI: 10.1002/pbc.22491
https://www.ncbi.nlm.nih.gov/pubmed/20486181

Dunkel I.J., Khakoo Y., Kernan N.A., Gershon T., Gilheeney S., Lyden D.C. et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatric Blood & Cancer. 2010. 55:55–9.
DOI: 10.1002/pbc.22504
https://www.ncbi.nlm.nih.gov/pubmed/20486171

Е

Eagle R.C., Shields C.L., Bianciotto C. et al. Histopathologic Observations After Intra-arterial Chemotherapy for Retinoblastoma. Arch. Ophthalmol. 2011. Vol.129, № 11. P.1416-1421.
DOI: 10.1001/archophthalmol.2011.223
https://pubmed.ncbi.nlm.nih.gov/21746972/

Ek U. Emotional reactions in patients and children after diagnosis and treatment of a malignant tumour in the eye // Child. Care. Helth. Dev. 2000. Vol.26, №5. P.415-428.
DOI: 10.1046/j.1365-2214.2000.00159.x
https://pubmed.ncbi.nlm.nih.gov/10998004/

Ek U., Seregard S., Jacobson L. et al. A prospective study of children treated for retinoblastoma: cognitive and visual outcomes in relation to treatment. Acta Ophthalmol Scand. 2002. Vol.80, №3. P.294–9.
DOI: 10.1034/j.1600-0420.2002.800312.x
https://pubmed.ncbi.nlm.nih.gov/12059869/

Eloy P., Dehainault C., Sefta M., Aerts I., Doz F., Cassoux N., etc. A parent-of-origin effect impacts the phenotype in low penetrance retinoblastoma families segregating the c.1981C>T/p.Arg661Trp mutation of RB1. 2016, PLoS Genet. 12, e1005888
https://doi.org/10.1371/journal.pgen.1005888

Elzomor H. et al. High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries // Ophthalmic Genetics. Taylor and Francis Ltd, 2015. Vol. 36, № 3. P. 287-289.
DOI:10.3109/13816810.2015.1016241

F

Fabian I.D., Onadim Z., Karaa E., Duncan C., Chowdhury T., Scheimberg I., Ohnuma S.I., Reddy M.A., Sagoo M.S. The management of retinoblastoma. Oncogene 2018; 37(12):1551–60.
doi: 10.1038/s41388-017-0050-x
https://pubmed.ncbi.nlm.nih.gov/29321667/

Fabian I.D., Reddy A., Sagoo M.S. Classification and staging of retinoblastoma. Community Eye Health. 2018. Vol. 31, №101. P.11-13. PMCID: PMC5998397
https://pubmed.ncbi.nlm.nih.gov/29915461/

Ferlay J., Colombet M., Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019. Vol.144, №8. P.1941-1953.
DOI 10.1002/ijc.31937. Epub 2018 Dec 6
https://pubmed.ncbi.nlm.nih.gov/30350310/

Fernandes A.G., Pollock B.D., Rabito F.A. Retinoblastoma in the United States: A 40-Year Incidence and Survival Analysis. J Pediatr Ophthalmol Strabismus. 2018 May 1;55(3):182-188.
DOI: 10.3928/01913913-20171116-03. Epub 2017 Dec 19.

Fluhs D., Anastassiou G., Wening J., Sauerwein W., Bornfeld N. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med Phys 2004; 31(6):1481–8.
doi: 10.1118/1.1755471

Francis J.H., Abramson D.H. Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma // Asia-Pacific Journal of Ophthalmology. 2014. Vol. 3. P. 241-256.
DOI: 10.1097/APO.0000000000000079
https://www.ncbi.nlm.nih.gov/pubmed/26107765

Francis J.H., Abramson D.H., Gobin Y.P., Marr B.P., Dunkel I.J., Riedel E.R. et al. Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: Six year review. PLoS One.2014;9:e84247.
DOI: 10.1371/journal.pone.0084247
http://europepmc.org/article/PMC/3896342

Francis J.H., Abramson D.H., Gobin Y.P., Marr B.P., Tendler I., Brodie S.E. et al. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Ophthalmology. 2015; 122:1016–22.
DOI: 10.1016/j.ophtha.2014.11.029
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994525/

Francis J.H., Abramson D.H., Ji X., Shields C.L., Teixeira L.F., Schefler A.C., Cassoux N., Hadjistilianou D., Berry J.L., Frenkel S., Munier F.L. Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy. JAMA Ophthalmol. 2017 Dec 1;135(12):1426-1429.
DOI: 10.1001/jamaophthalmol.2017.4600
https://www.ncbi.nlm.nih.gov/pubmed/29098285

Francis J.H., Barker C.A., Wolden S.L., McCormick B., Segal K., Cohen G., Gobin Y.P., Marr B.P., Brodie S.E., Dunkel I.J., Abramson D.H. Salvage. Adjuvant Brachytherapy After Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma. Int J Radiat Oncol 2013;87(3):517–23.
doi: 10.1016/j.ijrobp.2013.06.2045

Francis J.H., Brodie S.E., Marr B., Zabor E.C., Mondesire-Crump I., Abramson D.H. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four year experience. 2017, Ophthalmology 124, 488–495.
https://doi.org/10.1016/j. ophtha.2016.12.015

Francis J.H., Iyer S., Gobin Y.P. et al. Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy. Ophthalmology 2017; 124:1548-1555.
DOI: 10.1016/j.ophtha.2017.04.010
https://www.aaojournal.org/article/S0161-6420(17)30595-X/fulltext

Francis J.H., Kleinerman R., Seddon J., Abramson D. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. Gynecol. Oncol. 2012. Vol.124, №2. P.254–9.
DOI: 10.1016/j.ygyno.2011.10.019.
https://pubmed.ncbi.nlm.nih.gov/22027510/

Francis J.H., Levin A.M., Zabor E.C., Gobin Y.P., Abramson D.H. Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. PLoS One.2018;13:e0197081.
DOI: 10.1371/journal.pone.0197081
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965845/

Francis J.H., Marr B.P., Brodie S.E. et al. Intravitreal melphalan as salvage therapy for refractory retinal and subretinal retinoblastoma. Retinal Cases & Brief Reports. 2016. Vol.10, №4. P.357-360.
DOI: 10.1097/ICB.0000000000000262
https://pubmed.ncbi.nlm.nih.gov/26630243/

Francis J.H., Marr B.P., Brodie S.E., Abramson D.H. Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma. JAMA Ophthalmol. 2015 Dec;133(12):1459-63.
doi: 10.1001/jamaophthalmol.2015.3119.
https://pubmed.ncbi.nlm.nih.gov/26378741/

Francis J.H., Schaiquevich P., Buitrago E. et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014. №.121. P.1810 – 1817.
DOI: 10.1016/j.ophtha.2014.03.028
https://pubmed.ncbi.nlm.nih.gov/24819859/

Friedman D.L. et al. Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group // Pediatr. Blood Cancer. John Wiley and Sons Inc., 2017. Vol. 64, № 7.
DOI: 10.1002/pbc.26394
https://pubmed.ncbi.nlm.nih.gov/28019092/

Friedman D.L., Himelstein B., Shields C.L. et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. Journal of Clinical Oncology. 2000; 18(1): 12-17
DOI: 10.1200/JCO.2000.18.1.12.
https://www.ncbi.nlm.nih.gov/pubmed/10623688

Friedman D.N., Chou J., Oeffinger K. et al. Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. Cancer. 2016. Vol.122№5. P.773-81.
DOI: 10.1002/cncr.29704.
https://pubmed.ncbi.nlm.nih.gov/26755259/

Friedman D.N., Sklar C.A., Oeffinger K.C. et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60(4):694-699.
DOI: 10.1002/pbc.24280
https://www.ncbi.nlm.nih.gov/pubmed/22911631

Fujiwara T., Fujiwara M., Numoto K. et al. Second primary osteosarcomas in patients with retinoblastoma // Japanese Journal of Clinical Oncology. 2015. Vol.45, №12. P.1139–1145.
DOI: 10.1093/jjco/hyv140
https://pubmed.ncbi.nlm.nih.gov/26438540/

G

Gail M. Seigel, Dhaval K. Shah, Pia Mendoza, Ezster Szalai, Hans Grossniklaus, Yinghui Song, Jidong Shan. In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina. Oncoscience. 08, 2019.
https://doi.org/10.18632/oncoscience.489
http://www.impactjournals.com/oncoscience/index.php?pii=489

Galluzzi P., Hadjistilianou T., Cerase A., Toti P., Leonini S., Bracco S., de Francesco S., Galimberti D., Balducci D., Piu P., Monti L., Bellini M., Caini M., Rossi A. MRI helps depict clinically undetectable risk factors in advanced stage retinoblastomas. Neuroradiol J. 2015 Feb;28(1):53-61.
DOI: 10.15274/NRJ-2014-10103.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757124/

Gelli E., Pinto A.M., Somma S., Imperatore V., Cannone M.G., Hadjistilianou T., De Francesco S., Galimberti D., Currò A., Bruttini M., Mari F., Renieri A., Ariani F. Evidence of predisposing epimutation in retinoblastoma. Hum Mutat. 2019 Feb;40(2):201-206.
DOI: 10.1002/humu.2368
https://www.ncbi.nlm.nih.gov/pubmed/30427563

Gerrish A., Stone E., Clokie S., Ainsworth J.R., etc. Non-invasive diagnosis of retinoblastoma using cell-free DNA from aqueous humour. 2019, Br J Ophthalmol bjophthalmol.
https://doi.org/10.1136/bjophthalmol-2018-313005, 2018-313005
Harbour J.W. Molecular basis of low-penetrance retinoblastoma. 2001, Arch. Ophthalmol. 119, 1699–1704.
https://doi.org/10.1001/archopht.119.11.1699

Ghassemi F., Shields C.L. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Archives of Ophthalmology. 2012. 130(10): 1268-1271
DOI: 10.1001/archophthalmol.2012.1983.
https://www.ncbi.nlm.nih.gov/pubmed/23044940

Ghassemi F., Shields C.L., Ghadimi H., Khodabandeh A., Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmology. 2014 132 936–41.
DOI: 10.1001/jamaophthalmol.2014.414
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1865508

Ghiam B.K., Xu L/, Berry J.L. Aqueous Humor Markers in Retinoblastoma, a Review. Transl Vis Sci Technol. 2019 Apr 9;8(2):13.
DOI: 10.1167/tvst.8.2.13.
https://www.ncbi.nlm.nih.gov/pubmed/31019846

Gillison M.L., Chen R., Goshu E. et al. Human retinoblastoma is not caused by known pRb-inactivating human DNA tumor viruses // International Journal of Cancer. 2007. Vol. 120. P. 1482-1490.
DOI: 10.1002/ijc.22516
https://www.ncbi.nlm.nih.gov/pubmed/17205527

Gobin Y.P., Dunkel I.J., Marr B.P., Brodie S.E., Abramson D.H. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Archives of Ophthalmology. 2011. 129. 732-7.
DOI: 10.1001/archophthalmol.2011.5
https://www.ncbi.nlm.nih.gov/pubmed/21320950

Gobin Y.P., Dunkel I.J., Marr B.P., Francis J.H., Brodie S.E., Abramson D.H. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7(9):e44322. Epub 2012 Sep 18.
doi: 10.1371/journal.pone.0044322.
https://pubmed.ncbi.nlm.nih.gov/23028521/

Gohari M., Moghimi M., Aarafi H., Shajari A., Jafari-Nedooshan J., Lookzadeh MH., Mirjalili SR., Neamatzadeh H. Association of MTHFR 677C > T, 1298A > C and MTR 2756A > G Polymorphisms with Susceptibility to Childhood Retinoblastoma: A Systematic Review and Met-Analysis. Fetal and Pediatric Pathology. Feb-2020.
DOI: 10.1080/15513815.2020.1721738

Gombos D.S., Hungerford J., Abramson D.H. et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007; 114(7):1378-1383. 10.1016/j.ophtha.2007.03.074.
DOI: 10.1016/j.ophtha.2007.03.074
https://www.ncbi.nlm.nih.gov/pubmed/17613328

Gombos D.S., Hungerford J., Abramson D.H., Kingston J., Chantada G., Dunkel I.J., Antoneli C.B., Greenwald M., Haik B.G., Leal C.A., Medina-Sanson A., Schefler A.C., Veerakul G., Wieland R., Bornfeld N., Wilson M.W., Yu C.B. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007 Jul;114(7):1378-83.
doi: 10.1016/j.ophtha.2007.03.074.
https://pubmed.ncbi.nlm.nih.gov/17613328/

De Graaf P. et al. Guidelines for imaging retinoblastoma: Imaging principles and MRI standardization // Pediatric Radiology. 2012. Vol. 42, № 1. P. 2–14.
DOI: 10.1007/s00247-011-2201-5
https://pubmed.ncbi.nlm.nih.gov/21850471/

Grigorovski N., Lucena E., Mattosinho C., Parareda A., Ferman S., Catalá J. et al. Use of intra-arterial chemotherapy for retinoblastoma: Results of a survey. International Journal of Ophthalmology. 2014. 7:726–30.
DOI: 10.3980/j.issn.2222-3959.2014.04.26
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137215/

Guasti A., Leonini S., Bertelli E., Baldi R., Gennari P., Cioni S., Vallone I.M., Romano D., Casseri T., Guerrini L., La Rocca A.E., Scala P.G.D., De Francesco S., Hadjistilianou T., Bracco S. Intra-arterial chemotherapy for retinoblastoma: the dosimetric impact. Neuroradiology. 2019 Sep;61(9):1083-1091.
DOI: 10.1007/s00234-019-02260-7

Gudiseva HV, Berry JL, Polski A, Tummina SJ, O'Brien JM. Genes (Basel). Next-Generation Technologies and Strategies for the Management of Retinoblastoma. 2019 Dec 11;10(12). pii: E1032.
DOI: 10.3390/genes10121032
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947430/

Gündüz K., Günalp I., Yalçindağ N., Unal E., Taçyildiz N., Erden E., Geyik P.O. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology. 2004 Oct;111(10):1917-24.
doi: 10.1016/j.ophtha.2004.04.016.
https://pubmed.ncbi.nlm.nih.gov/15465557/

Gunduz K., Kose K., Kurt R.A., Suren E., Tacyildiz N., Dincaslan H., Ünal E., Erden E., Heper A.O. Retinoblastoma in Turkey: results from a tertiary care center in Ankara. Journal of Pediatric Ophthalmology and Strabismus. 2013 50 296–303.
DOI: 10.3928/01913913-20130730-02
https://www.ncbi.nlm.nih.gov/pubmed/23937863

H

Habib L.A., Francis J.H., Fabius A.W., Gobin P.Y., Dunkel I.J., Abramson D.H. Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: The first 10 years. British Journal of Ophthalmology. 2018; 102:272–275.
DOI: 10.1136/bjophthalmol-2017-310328
https://www.ncbi.nlm.nih.gov/pubmed/28600304

Hardell L, Dreifaldt AC. Breast-feeding duration and the risk of malignant diseases in childhood in Sweden. Eur J Clin Nutr. 2001; 55(3):179–185.
DOI: 10.1038/sj.ejcn.1601142

Hargreave M., Jensen A., Toender A., Andersen K.K., Kjaer S.K. Fertility treatment and childhood cancer risk: a systematic meta-analysis. Fertil Steril. 2013;100(1):150–161.
DOI: 10.1016/j.fertnstert.2013.03.017
https://www.ncbi.nlm.nih.gov/pubmed/18097988

Hasanreisoglu M., Saktanasate J., Schwendeman R., Shields J.A., Shields C.L. Indocyanine Green-Enhanced Transpupillary Thermotherapy for Retinoblastoma: Analysis of 42 Tumors. J Pediatr Ophthalmol Strabismus. 2015 Nov-Dec;52(6):348-54.
doi: 10.3928/01913913-20150929-17.
https://pubmed.ncbi.nlm.nih.gov/26584748/

Heck J.E., Lombardi C.A., Meyers T.J. et al. Perinatal characteristics and retinoblastoma // Cancer Causes & Control. 2012. Vol. 23. N 9. P. 1567-1575.
DOI: 10.1007/s10552-012-0034-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429932/

Heck J.E., Omidakhsh N., Azary S., Ritz B., von Ehrenstein O.S., Bunin G.R., Ganguly A. A case-control study of sporadic retinoblastoma in relation to maternal health conditions and reproductive factors: a report from the Children's Oncology group. BMC Cancer. 2015 Oct 19;15:735.
DOI: 10.1186/s12885-015-1773-0
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615328/

Heck J.E., Park A.S., Qiu J. et al. Retinoblastoma and ambient exposure to air toxics in the perinatal period //Journal of Exposure Science and Environmental Epidemiology. 2015. Vol. 25. P. 182-186.
DOI: 10.1038/jes.2013.84
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059784/

Hiçsönmez A., Güney Y., Dizman A., Dirican B., Arslan Y., Atakul T., Uysal H., Gündüz K., Taçyıldız N., Ünal E., Dinçaslan H., Andrieu M.N. Challenges and differences in external radiation therapy for retinoblastoma: from standard techniques to new developments. Tumori. 2017 Sep 18;103(5):438-442. PMID: 26350182.
doi: 10.5301/tj.5000406

Honavar S.G. Orbital Retinoblastoma. In: Ramasubramanian A., Shields C.L., editors. Retinoblastoma. New Delhi, India: Jaypee Brothers Medical Publishers. 2012. pp. 167-78.

Honavar S.G., Manjandavida F.P., Reddy V.A.P. Orbital retinoblastoma: an update. Indian J Ophthalmol 2017;65(6):435–42.
doi: 10.4103/ijo.IJO_352_15.
https://pubmed.ncbi.nlm.nih.gov/28643706/

Honavar S.G., Singh A.D. Management of advanced retinoblastoma. Ophthalmology Clinics of North America.2005. 18:65–73.viii
DOI: 10.1016/j.ohc.2004.09.001
https://www.ophthalmology.theclinics.com/article/S0896-1549(04)00128-2/fulltext

Honavar S.G., Singh A.D., Shields C.L., Meadows A.T., Demirci H., Cater J., Shields J.A. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002 Jul;120(7):923-31.
doi: 10.1001/archopht.120.7.923.
https://pubmed.ncbi.nlm.nih.gov/12096963/

Houston S.K., Murray T.G., Wolfe S.Q., Fernandes C.E., Current Update on Retinoblastoma // International Ophthalmology Clinics. 2011. Vol. 51. N 1. P. 77-91.
DOI: 10.1097/IIO.0b013e3182010f29
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079394/

Hua J., Gang S., Yizhou J., Jing Z. Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. Journal of Cancer Research and Therapeutic Oncology. 2018; 14:106–110.
DOI: 10.4103/jcrt.JCRT_722_17
https://www.ncbi.nlm.nih.gov/pubmed/29516970

Huang S, Rutar T, Bloomer M, et al. Analysis of clinical misdiagnosis in children treated with enucleation. Archives of Ophthalmology. 2010;128:1009-1013.
DOI: 10.1001/archophthalmol.2010.153
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/426090

De la Huerta I., Seider M.I., Hetts S.W., Damato B.E. Delayed cerebral infarction following intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmology.2016; 134:712–4.
DOI: 10.1001/jamaophthalmol.2016.0025
https://www.ncbi.nlm.nih.gov/pubmed/27077487

Hu H, Zhang W, Wang Y, Huang D, Shi J, Li B, Zhang Y, Zhou Y. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018 Apr 23;18(1):107.
doi: 10.1186/s12886-018-0772-8.
https://pubmed.ncbi.nlm.nih.gov/30361279/

Hurwitz R.L., Shields C.L., Shields J.A. et al. Retinoblastoma. Principles and practice of pediatric oncology. Philadelphia: Lippincott, Williams and Wilkins, 2006. P. 865-886.

I

Imhof S.M., Moll A.C., Schouten-van Meeteren A.Y.: Stages of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands // British Journal of Ophthalmology. 2006. Vol. 90. P. 875-878.
DOI: 10.1136/bjo.2005.089375
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857137/

Imperatore V., Pinto A.M., Gelli E., Trevisson E., Morbidoni V., Frullanti E., Hadjistilianou T., De Francesco S., Toti P., Gusson E., Roversi G., Accogli A., Capra V., Mencarelli M.A., Renieri A., Ariani F. Parent-of-origin effect of hypomorphic pathogenic variants and somatic mosaicism impact on phenotypic expression of retinoblastoma. Eur J Hum Genet. 2018 Jul;26(7):1026-1037.
DOI: 10.1038/s41431-017-0054-6.
https://www.nature.com/articles/s41431-017-0054-6

J

Jabbour P., Chalouhi N., Tjoumakaris S., Gonzalez L.F., Dumont A.S., Chitale R., Rosenwasser R., Bianciotto C.G., Shields C. Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr. 2012 Sep;10(3):175-81. Epub 2012 Jul 13.
doi: 10.3171/2012.5.PEDS1277
https://pubmed.ncbi.nlm.nih.gov/22793160/

Jairam V., Roberts K.B., Yu J.B. Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e151-5. PMID: 23273995; PMCID: PMC3636568.
doi: 10.1016/j.ijrobp.2012.10.007

Jaradat I., Mubiden R., Salem A., Abdel-Rahman F., Al-Ahmad I., Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther. 2012; 5:107-117.
doi: 10.5144/1658-3876.2012.107

Jemal A., Devesa S., Fears T., Fraumeni J. Retinoblastoma incidence and sunlight exposure // British Journal of Cancer. 2000. Vol. 82. № 11. P. 1875-1878.
DOI: 10.1054/bjoc.2000.1215
https://www.ncbi.nlm.nih.gov/pubmed/10839306

Johnson K.J., Poynter J.N., Ross J.A. et al. Pediatric germ cell tumors and maternal vitamin supplementation: a Children's Oncology Group study // Cancer Epidemiology, Biomarkers & Prevention 2009. Vol.18. N 10. P. 2661-2664.
DOI: 10.1158/1055-9965.EPI-09-0462
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759848/

Johnson K.P., McLean A., Rubin G.S., Papastefanou V.P., Hussain A., Cai Y. et al. Microperimetry and swept-source optical coherence tomography in the assessment of the preferred retinal locus in a child with macular retinoblastoma in the remaining eye. J Am Assoc Pediatr Ophthalmol Strabismus. Epub 2018 Nov 28. 2019 Apr;23(2):115-117.
doi: 10.1016/j.jaapos.2018.11.003.

de Jong M.C., Kors WA., de Graaf P., Castelijns J.A., Moll A.C., Kivelä T. The Incidence of Trilateral Retinoblastoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2015 Dec;160(6):1116-1126.e5.
DOI: 10.1016/j.ajo.2015.09.009
https://www.ajo.com/article/S0002-9394(15)00561-9/fulltext

de Jong M.C., Kors W.A., Moll A.C., de Graaf P., Castelijns J.A., Jansen R.W., Gallie B., Soliman S.E., Shaikh F., Dimaras H., Kivelä T.T. Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Ophthalmology. 2019 Nov 9. pii: S0161-6420(19)32215-8.
DOI: 10.1016/j.ophtha.2019.10.040.
https://www.aaojournal.org/article/S0161-6420(19)32215-8/fulltext

K

Kaatsch P., Spix C.: German Childhood Cancer Registry - Jahresbericht / Annual Report 2013/14 (1980-2013). Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI). Universitätsmedizin der Johannes Gutenberg-Universität Mainz. 2014.
http://www.kinderkrebsregister.de/ dkkr/ veroeffentlichungen/ jahresbericht/ jahresbericht-201314.html

Kaliki S., Mittal P., Mohan S. Bilateral advanced (group D or E) intraocular retinoblastoma: outcomes in 72 Asian Indian patients. Eye (Lond). 2019; 33 (8): 1297–304.
doi:10.1038/s41433-019-0409-z
https://pubmed.ncbi.nlm.nih.gov/30932036/

Kaliki S., Shields C.L. Retinoblastoma: achieving new standards with methods of chemotherapy. Indian Journal of Ophthalmology. 2015. 63(2):103-9.
DOI: 10.4103/0301-4738.154369
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399117/

Kaliki S., Shields C.L., Rojanaporn D., Al-Dahmash S., McLaughlin J.P., Shields J.A. et al. High-risk retinoblastoma based on international classification of retinoblastoma: Analysis of 519 enucleated eyes.Ophthalmology. 2013, 120:997-1003.
DOI: 10.1016/j.ophtha.2012.10.044
https://www.ncbi.nlm.nih.gov/pubmed/23399379

Kaliki S., Shields C.L., Shah S.U., Eagle R.C. Jr., Shields J.A., Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Archives of Ophthalmology. 2011. 129:1422–7.
DOI: 10.1001/archophthalmol.2011.289
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1106482

Kaliki S., Tahiliani P., Mishra D.K., Srinivasan V., Ali M.H., Reddy V.A. Optic nerve infiltration by retinoblastoma: predictive clinical features and outcome. Retina. 2016; 36:1177–83.
https://doi.org/10.1097/IAE.0000000000000861

Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Japanese Journal of Clinical Oncology. 2003. 33:601-7.
https://www.ncbi.nlm.nih.gov/pubmed/14769836

Kao L.Y., Su W.W., Lin Y.W. Retinoblastoma in Taiwan: survival and clinical characteristics 1978-2000. Jpn J Ophthalmol. 2002 Sep-Oct;46(5):577-80.
doi: 10.1016/s0021-5155(02)00546-4.
https://pubmed.ncbi.nlm.nih.gov/12457919/

Kapatai G., Brundler M.-A., Jenkinson H., Kearns P., etc. Gene expression profiling identifies different sub-types of retinoblastoma. 2013, Br. J. Cancer 109, 512–525.
https://doi.org/10.1038/bjc.2013.283

Kelly K.R., Gallie B.L., Steeves J.K.E. Early monocular enucleation selectively disrupts neural development of face perception in the occipital face area. Exp Eye Res. 2019 Jun;183:57-61.
DOI: 10.1016/j.exer.2018.09.013

Kim J.W., Shah S.N., Green S., O'Fee J., Tamrazi B., Berry J.L. Tumour size criteria for Group D and E eyes in the International Classification System for Retinoblastoma: effects on rates of globe salvage and high-risk histopathologic features. Acta Ophthalmol. 2020 Feb; 98(1):e121-e125.
doi: 10.1111/aos.14222.

Kim J.-Y., Park Y. Treatment of Retinoblastoma: The Role of External Beam Radiotherapy. Yonsei Med J 2015;56(6):1478.
doi: 10.3349/ymj.2015.56.6.1478
https://pubmed.ncbi.nlm.nih.gov/26446627/

Kiss S., Leiderman Y., Mukai S. Diagnosis, Classification, and Treatment of Retinoblastoma // International Ophthalmology Clinics. 2008. Vol. 48. N 2. P. 135-147.
DOI: 10.1097/IIO.0b013e3181693670
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.799.9734&rep=rep1&type=pdf

Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death // British Journal of Ophthalmology. 2009. Vol. 93. P. 1129-1131.
DOI: 10.1136/bjo.2008.150292
https://www.ncbi.nlm.nih.gov/pubmed/19704035

Kivelä T., Eskelin S., Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011; 118(8): 1681-1686. tha.2011.02.005.
DOI: 10.1016/j.ophtha.2011.02.005
https://www.ncbi.nlm.nih.gov/pubmed/21813093

Kivelä T., Hadjistilianou T. Neonatal Retinoblastoma. Asia Pac J Oncol Nurs. 2017 Jul-Sep; 4(3): 197–204.
DOI: 10.4103/apjon.apjon_18_17
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473090/

Kleinerman R.A., Schonfeld S.J., Tucker M.A. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012 Oct 4;2(1):15.
doi: 10.1186/2045-3329-2-15
https://pubmed.ncbi.nlm.nih.gov/23036192/

Kleinerman R.A., Tucker M.A., Abramson D.H., Seddon J.M., Tarone R.E., Fraumeni J. Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007 Jan 3;99(1):24-31.
doi: 10.1093/jnci/djk002. PMID: 17202110.
https://pubmed.ncbi.nlm.nih.gov/17202110/

Kleinerman R.A., Tucker M.A., Sigel B.S., Abramson D.H., Seddon J.M., Morton L.M. Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. J Natl Cancer Inst. 2019 Sep 1;111(9):961-969.
doi: 10.1093/jnci/djy227.
https://pubmed.ncbi.nlm.nih.gov/30698734/

Kleinerman R.A., Tucker M.A., Tarone R.E. et al. Risk of new cancers after radiotherapy in long-term survi vors of retinoblastoma: an extended follow-up. Journal of Clinical Oncology. 2005; 23(10): 2272–2279.
DOI: 10.1200/JCO.2005.05.054
https://www.ncbi.nlm.nih.gov/pubmed/15800318

Kleinerman R.A., Yu C.L., Little M.P., Li Y., Abramson D., Seddon J., Tucker M.A. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012 Mar 20;30(9):950-7.
doi: 10.1200/JCO.2011.37.0239.
https://pubmed.ncbi.nlm.nih.gov/22355046/

Kletke S.N., Feng Z.X., Hazrati L.N., Gallie B.L., Soliman S.E. Clinical Predictors at Diagnosis of Low-Risk Histopathology in Unilateral Advanced Retinoblastoma. Ophthalmology. 2019 Sep;126(9):1306-1314.
DOI: 10.1016/j.ophtha.2019.04.003.
https://www.aaojournal.org/article/S0161-6420(19)30013-2/fulltext

Klufas M.A. et al. Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. American Journal of Neuroradiology. 2012. 33 (8) 1608-14.
DOI: 10.3174/ajnr.A3019
https://www.ncbi.nlm.nih.gov/pubmed/22442047

Kooi I.E., Mol B.M., Massink M.P.G., Ameziane N., Meijers-Heijboer H., etc. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. 2016a, Sci. Rep. 6, 25264
https://doi.org/10.1038/srep25264

Kooi I.E., Mol B.M., Massink M.P.G., de Jong M.C., de Graaf P., etc. A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression. 2016b, PLoS One 11, e0153323.
https://doi.org/10.1371/journal.pone.0153323

Kooi I.E., Mol B.M., Moll A.C., van der Valk P., etc. Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression. 2015, EBioMedicine 2, 660–670
https://doi.org/10.1016/j.ebiom.2015.06.022

Kremens B., Wieland R., Reinhard H., Neubert D., Beck J.D., Klingebiel T., Bornfeld N., Havers W. Retinoblastoma: Highdose chemotherapy with autologous stem cell rescue in children with retinoblastoma; Bone Marrow Transplant. 2003; 31, 281-284.
doi: 10.1038/sj.bmt.1703832

Krishna S.M., Yu G-P., Finder P.T. The effect of race on the incidence of retinoblastoma // Journal of Pediatric Ophthalmology and Strabismus. 2009. Vol. 46. N 5. P. 288-293.
DOI: 10.3928/01913913-20090903-06
https://www.ncbi.nlm.nih.gov/pubmed/19791726

L

Lambert M.P., Shields C., Meadows A.T. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatric Blood & Cancer. 2008; 50(2):223-226.
DOI: 10.1002/pbc.21155.
https://www.ncbi.nlm.nih.gov/pubmed/17278120

Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. Journal of Clinical Oncology. 2012; 30(10):1023-1024. JCO.2011.39.4254.
DOI: 10.1200/JCO.2011.39.4254
https://www.ncbi.nlm.nih.gov/pubmed/22370322

Leahey A.M. Systemic chemotherapy: A pediatric oncology perspective. In: Ramasubramanian A, Shields CL, editors. Retinoblastoma. New Delhi, India: Jaypee Brothers Medical Publishers. 2012. pp. 81–5.

Lea-Leal C., Flores-Rojo M., Medina-Samson A. et al. A multicenter report from the Mexican retinoblastoma group // British Journal of Ophthalmology. 2004. Vol. 88. P. 1074-1077.
DOI: 10.1136/bjo.2003.035642
https://www.ncbi.nlm.nih.gov/pubmed/15258028

Leal-Leal C.A., Rivera-Luna R., Flores-Rojo M. et al. Survival in extra-orbital metastatic retinoblastoma: treatment results // Clinical and Translational Oncology. 2006. Vol. 8. P. 39-44.
DOI: 10.1007/s12094-006-0093-x
https://www.ncbi.nlm.nih.gov/pubmed/16632438

Leal-Leal C.A., Rivera-Luna R., Flores-Rojo M., Juárez-Echenique J.C., Ordaz J.C., Amador-Zarco J. Survival in extra-orbital metastatic retinoblastoma: Treatment results. Clinical and Translational Oncology.2006. 8:39-44.
DOI: 10.1007/s12094-006-0093-x
https://www.ncbi.nlm.nih.gov/pubmed/16632438

Lee S., Yoo K., Sung K., Kim J., Cho E., Koo H., Chung S., Kang S., Oh S., Ham D., Kim Y. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant. 2008; 42(6): 385-391.
doi: 10.1038/bmt.2008.181

Lee V., Subak-Sharpe I., Hungerford J.L., Davies N.P., Logani S. Exposure of primary orbital implants in postenucleation retinoblastoma patients // Ophthalmology. 2000. № 5. P. 940-945.
DOI:10.1016/s0161-6420(00)00016-6

Leiderman YI, Kiss S, Mukai S. Molecular genetics of RB1--the retinoblastoma gene. Semin Ophthalmol. 2007;22(4):247–254.
DOI: 10.1080/08820530701745165
https://www.ncbi.nlm.nih.gov/pubmed/18097988

Levin A.M., Francis J.H., McFadden M., Brodie S., Gobin Y.P., Abramson D.H. Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes. PLoS One. 2019;14:e0210647.
DOI: 10.1371/journal.pone.0210647
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334963/

Levin M.H., Gombos D.S., O'Brien J.M. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol. 2011; 129(11):1487-1489.

Li J., Di C., Jing J., Di Q., Nakhla J., Adamson D.C. OTX2 is a therapeutic target for retinoblastoma and may function as a common factor between C-MYC, CRX, and phosphorylated RB pathways. 2015. Int. J. Oncol. 47, 1703–1710.
https://doi.org/10.3892/ijo.2015.3179

Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmology Clinics of North America. 2005; 18(1): 41-53.
DOI: 10.1016/j.ohc.2004.11.003
https://www.ncbi.nlm.nih.gov/pubmed/15763190

Little M.P., Kleinerman R.A., Stiller C.A. et al. Analysis of retinoblastoma age incidence data using a fully stochastic cancer model // International Journal of Cancer. 2012. Vol. 130. N 3. P. 631-640.
DOI: 10.1002/ijc.26039.
https://www.ncbi.nlm.nih.gov/pubmed/21387305

Li W.L. et al. A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families // J. Mol. Diagnostics. Elsevier B.V., 2016. Vol. 18, № 4. P. 480–493.
DOI: 10.1016/j.jmoldx.2016.02.006
https://pubmed.ncbi.nlm.nih.gov/27155049/

Lombardi C., Ganguly A., Bunin G.R. et al. Maternal diet during pregnancy and unilateral retinoblastoma // Cancer Causes & Control. 2015. Vol. 26. N 3. P. 387-397.
DOI: 10.1007/s10552-014-0514-z
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334703/

Lucas J.T., McGee R., Billups C.A., Qaddoumi I., Merchant T.E., Brennan R.C., Wu J., Wilson M.W. Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma. Br J Ophthalmol 2019; 103(5):699–703.
doi: 10.1136/bjophthalmol-2018-311923

Lu J.E., Francis J.H., Dunkel I.J., Shields C.L., Yu M.D., Berry J.L., Kogachi K., Skalet A.H., Miller A.K., Santapuram P.R., Daniels A.B., Abramson D.H. Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017. Br J Ophthalmol. 2019 Sep;103(9):1272-1277.
doi: 10.1136/bjophthalmol-2018-312915.

Lukusa А.К., Aloni M.N., Kadima-Tshimanga B. et al. Retinoblastoma in the Democratic Republic of Congo: 20-Year Review from a Tertiary Hospital in Kinshasa // Journal of Cancer Epidemiology. 2012. Article ID 920468.
DOI: 10.1155/2012/920468
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350961/

Lumbroso L., Doz F., Urbieta M., Levy C., Bours D., Asselain B., Vedrenne J., Zucker J.M., Desjardins L. Chemothermotherapy in the management of retinoblastoma. Ophthalmology. 2002 Jun;109(6):1130-6.
doi: 10.1016/s0161-6420(02)01053-9.
https://pubmed.ncbi.nlm.nih.gov/12045055/

Lumbroso-Le Rouic L, Savignoni A, Levy-Gabriel C, et al. Treatment of retinoblastoma: the Institut Curie experience on a series of 730 patients (1995 to 2009). J Fr Ophtalmol. 2015; 38(6):535-541
DOI: 10.1016/j.jfo.2015.04.002
https://www.ncbi.nlm.nih.gov/pubmed/25976136

Luo G., Deng Y.P. Retinoblastoma: concerning its initiation and treatment // International Journal of Ophthalmology. 2013. Vol. 6. N 3. P. 397-401.
DOI: 10.3980/j.issn.2222-3959.2013.03.26
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693027/

Lyle C., Wilson M., Li C., Kaste S. Comparison of Orbital Volumes in Enucleated Patients With Unilateral Retinoblastoma: Hydroxyapatite Implants Versus Silicone Implants // Plastic & Reconstructive Surgery. 2007. № 5. P. 393-396.
DOI: 10.1097/IOP.0b013e3181462ca8

M

MacCarthy A., Bayne A.M., Brownbill P.A. et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004 // British Journal of Cancer. 2013. Vol. 108. P. 2455-2463.
DOI: 10.1038/bjc.2013.228.
https://www.ncbi.nlm.nih.gov/pubmed/23674091

MacCarthy A., Bayne A.M., Draper G.J., Eatock E.M. et al. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol. 2009 Sep;93(9):1159-62.
doi: 10.1136/bjo.2008.146035.
https://pubmed.ncbi.nlm.nih.gov/19704040/

MасСагthу A., Birch J. M., Drареr G.J. et al. Retinoblastoma: treatment and survival in Great Britain 1963 to 2002 // British Journal of Ophthalmology. 2009. Vol. 93. P. 33-39.
DOI: 10.1136/bjo.2008.139626.
https://www.ncbi.nlm.nih.gov/pubmed/18838414

MacCarthy A., Draper G., Steliarova-Foucher E., Kingston J. Retinoblastoma incidence and survival in European children (1978-1997) report from the Automated childhood cancer information system project // Eur. J. cancer. 2006. Vol. 10. P. 2092-2102.
DOI: 10.1016/j.ejca.2006.06.003
https://www.researchgate.net/publication/6867964_Retinoblastoma_incidence_and_survival_in_European_children_1978-1997_Report_from_the_Automated_Childhood_Cancer_Information_System_Project


Maidana D.E., Pellegrini M., Shields J.A., Shields C.L. Choroidal thickness after intraarterial chemotherapy for retinoblastoma.Retina.2014; 34:2103–9.
DOI: 10.1097/IAE.0000000000000190.
https://www.ncbi.nlm.nih.gov/pubmed/24936943

Mallipatna A.C., Dimaras H., Chan H.S., Héon E., Gallie B.L. Periocular topotecan for intraocular retinoblastoma. Archives of Ophthalmology. 2011. 129:738-45.
DOI: 10.1001/archophthalmol.2011.130.
https://www.ncbi.nlm.nih.gov/pubmed/21670340

Manjandavida F.P., Stathopoulos C., Zhang J., Honavar S.G., Shields C.L. Intra-arterial chemotherapy in retinoblastoma. A paradigm change. Indian Journal of Ophthalmology.2019 Jun. 67(6):740-754.
DOI: 10.4103/ijo.IJO_866_19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552585/

Mao Y., Wu Z., Yang H., Lin S., Zheng J. Measurement of intraocular concentrations of etoposide after systemic and local administration. Yan Ke Xue Bao.2004. 20:178-80.
https://www.ncbi.nlm.nih.gov/pubmed/15499727

Marees T., van Leeuwen F.E., de Boer M.R. et al. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 2009 Dec;45(18):3245-53.
doi: 10.1016/j.ejca.2009.05.011.
https://pubmed.ncbi.nlm.nih.gov/19493675/

Marees T., Moll A.C., Imhof S.M., de Boer M.R. et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9.
doi: 10.1093/jnci/djn394
https://pubmed.ncbi.nlm.nih.gov/19066271/

Marr B., Gobin P.Y., Dunkel I.J., Brodie S.E., Abramson D.H. Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma. Middle East Afr J Ophthalmol. 2010 Jul;17(3):207-9.
doi: 10.4103/0974-9233.65492.
https://pubmed.ncbi.nlm.nih.gov/20844675/

Marr B.P., Brodie S.E., Dunkel I.J., Gobin Y.P., Abramson D.H. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 2012; 96(10):1300–3.
doi: 10.1136/bjophthalmol-2012-301925.
https://pubmed.ncbi.nlm.nih.gov/22863945/

Marr B.P., Dunkel I.J., Linker A., Abramson D.H. Periocular carboplatin for retinoblastoma: Long-term report (12 years) on efficacy and toxicity. British Journal of Ophthalmology.2012; 96:881-3.
DOI: 10.1136/bjophthalmol-2011-300517.
https://www.ncbi.nlm.nih.gov/pubmed/22328819

Martynov L., Letyagin I., Trofimov I., Matinyan N. Anesthetic Management of Superselective Ophtalmic Arterial Chemotherapy for Retinoblastoma in Children. SIOP abstracts. 48th congress of the international society of paediatric oncology (SIOP). Dublin, Ireland. October 19-22, 2016.

Mastrangelo D., Francesco S., LеоnаrdоА. et al. Retinoblastoma epidemiology: Does the evidence mаtеr? // European Journal of Cancer. 2007. Vol. 43. P. 1596-1600.
DOI: 10.1016/j.ejca.2007.04.019
https://www.ncbi.nlm.nih.gov/pubmed/17543516

Mastrangelo D., Loré C., Grasso G. Retinoblastoma as an epigenetic disease: a proposal // Journal of Cancer Treatment and Research. 2011. N. 2. P. 362-371.
DOI: 10.4236/jct.2011.23049
https://www.scirp.org/journal/paperinformation.aspx?paperid=6661

Mastrangelo D., Loré C., Grasso G. The Epigenetic Origin of Retinoblastoma // EUROPEAN OPHTHALMIC REVIEW. 2012. Vol. 6. N 2. P. 130-135.
https://www.touchophthalmology.com/the-epigenetic-origin-of-retinoblastoma/

Materin M.A., Bianciotto C.G., Wu C., Shields C.L. Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study. Retina. 2012 Sep;32(8):1601-7.
doi: 10.1097/IAE.0b013e3182437e70.
https://pubmed.ncbi.nlm.nih.gov/22466484/

Matsubara H., Makimoto A., Higa T., Kawamoto H., Sakiyama S., Hosono A., Takayama J., Takaue Y., Murayama S., Sumi M., Kaneko A., Ohira M. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005; 35 (8): 763-766.
doi: 10.1038/sj.bmt.1704882

McDaid C., Hartley S., Bagnall A-M et al. Systematic review of effectiveness of different treatments for childhood retinoblastoma // Health Technology Assessment. 2005. Vol. 9. N 48. P. 164.
DOI: 10.3310/hta9480
https://www.ncbi.nlm.nih.gov/pubmed/16336843

McEvoy J., Flores-Otero J., Zhang J., Nemeth K., etc. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. 2011, Cancer Cell 20, 260–275.
https://doi.org/10.1016/j.ccr.2011.07.005

Meel R., Radhakrishnan V., Bakhshi S. Current therapy and recent advances in the management of retinoblastoma. Indian J Med Paediatr Oncol 2012;33(2):80–8.
doi: 10.4103/0971-5851.99731.
https://pubmed.ncbi.nlm.nih.gov/22988349/

Mehta M., Sethi S., Pushker N. et al. Retinoblastoma // Singapore Medical Journal. 2012. Vol. 53. N 2. P. 128-135.
https://www.ncbi.nlm.nih.gov/pubmed/22337189

Mendoza P.R., Grossniklaus H.E. Therapeutic options for retinoblastoma // Cancer Control. H. Lee Moffitt Cancer Center and Research Institute, 2016. Vol. 23, № 2. P. 99–109.
DOI:10.1177/107327481602300203

Merchant T.E., Gould C.J., Wilson M.W., Hilton N.E., Rodriguez-Galindo C., Haik B.G. Episcleral plaque brachytherapy for retinoblastoma. Pediatric Blood&Cancer. 2004. 43(2): 134-9.
DOI: 10.1002/pbc.20094
https://www.ncbi.nlm.nih.gov/pubmed/15236279

Michaels S.T., Abruzzo T.A., Augsburger J.J., Corrêa Z.M., Lane A., Geller J.I. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. Journal of Pediatric Hematology/Oncology. 2016; 38:65–9.
DOI: 10.1097/MPH.0000000000000471
https://www.ncbi.nlm.nih.gov/pubmed/26583615

Mills M.B., Hudgins L., Balise R. R. et al. Mutation Risk Associated with Paternal and Maternal Age in a Cohort of Retinoblastoma Survivors. // Human Genetics. 2011. Vol. 131. N 7. P. 1115-1122.
DOI: 10.1007/s00439-011-1126-2
https://www.ncbi.nlm.nih.gov/pubmed/22203219

Moll A.C., Imhof S.M., Schouten-Van Meeteren A.Y., Kuik D.J., Hofman P., Boers M. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology. 2001 Jun;108(6):1109-14.
doi: 10.1016/s0161-6420(01)00562-0.
https://pubmed.ncbi.nlm.nih.gov/11382638/

Moon J., Choung H.K., Yoo Y.J., Kim N., Khwarg SI. Second Primary Rhabdomyosarcoma in Nonhereditary Unilateral Retinoblastoma Not Treated with Radiotherapy. Korean J Ophthalmol. 2017 Aug;31(4):370-371. doi: 10.3341/kjo.2017.0011.
https://pubmed.ncbi.nlm.nih.gov/28682022/

Mourits D.L., Moll A.C., Bosscha M.I., Tan H.S., Hartong D.T. Orbital implants in retinoblastoma patients: 23 years of experience and a review of the literature // Acta Ophthalmol. 2016. № 94. P. 165-174.
DOI: 10.1111/aos.12915

Mouw K.W., Sethi R.V., Yeap B.Y., MacDonald S.M., Chen Y.-L.E., Tarbell N.J., Yock T.I., Munzenrider J.E., Adams J., Grabowski E., Mukai S., Shih H.A. Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys 2014; 90(4):863–9.
doi:10.1016/j.ijrobp.2014.07.031.
https://pubmed.ncbi.nlm.nih.gov/25227498/

Muen W.J., Kingston J.E., Robertson F. et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 2012; 119(3):611-616
DOI: 10.1016/j.ophtha.2011.08.045.
https://www.ncbi.nlm.nih.gov/pubmed/22197434

Munier F.L. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014 Dec;35(4):193-207.
doi: 10.3109/13816810.2014.973045
https://pubmed.ncbi.nlm.nih.gov/25321846/

Munier F.L., Beck-Popovic M., Balmer A., et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011. 31(3):566-573. IAE.0b013e318203c101.
DOI: 10.1097/IAE.0b013e318203c101
https://www.ncbi.nlm.nih.gov/pubmed/21273941

Munier F.L., Beck-Popovic M., Chantada G.L., Cobrinik D., Kivelä T.T., Lohmann D. et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity."
Prog Retin Eye Res 2019;73:100764.
doi: 10.1016/j.preteyeres.2019.05.005
https://pubmed.ncbi.nlm.nih.gov/31173880/

Munier F.L., Gaillard M.C., Balmer A. et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. British Journal of Ophthalmology. 2012; 96(8): 1078-1083.
DOI: 10.1136/bjophthalmol-2011-301450.
https://www.ncbi.nlm.nih.gov/pubmed/22694968

Munier F.L., Gaillard M.C., Decembrini S., Bongiovanni M., Beck-Popovic M. Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study. Ocul Oncol Pathol. 2017 Jul;3(2):149-155. Epub 2016 Dec 29
doi: 10.1159/000453617.
https://pubmed.ncbi.nlm.nih.gov/28868287/

Munier F.L., Mosimann P., Puccinelli F., Gaillard M.C., Stathopoulos C., Houghton S. et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: Evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. British Journal of Ophthalmology.2017;101:1086–93.
DOI: 10.1136/bjophthalmol-2016-309298
https://www.ncbi.nlm.nih.gov/pubmed/27927678

Munier F.L., Moulin A., Gaillard M.C., Bongiovanni M., Decembrini S., Houghton S., Beck-Popovic M., Stathopoulos C.. Intracameral Chemotherapy for Globe Salvage in Retinoblastoma with Secondary Anterior Chamber Invasion. Ophthalmology. 2018 Apr;125(4):615-617. Epub 2017 Dec 6.
doi: 10.1016/j.ophtha.2017.11.010.

Murakami N., Suzuki S., Ito Y., Yoshimura R., Inaba K., Kuroda Y., Morota M., Mayahara H., Sakudo M., Wakita A., Okamoto H., Sumi M., Kagami Y., Nakagawa K., Ohtomo K., Itami J. 106Ruthenium Plaque Therapy (RPT) for Retinoblastoma. Int J Radiat Oncol 2012;84(1):59–65. doi: 10.1016/j.ijrobp.2011.11.002

Murphree A.L. Intraocular Retinoblastoma: the Case for a New Group Classification. Ophthalmology Clinic of North America. 2005. 18: 41-53/
DOI: 10.1016/j.ohc.2004.11.003
PMID: 15763190
https://www.ncbi.nlm.nih.gov/pubmed/15763190
https://pubmed.ncbi.nlm.nih.gov/15763190/

Murphree A. Linn, Jonathan W. Kim. Retinoblastoma: Focal Therapy – Laser Treatment, Cryotherapy, and Brachytherapy. Clinical Ophthalmic Oncology. Pp 109-118. 2014.
DOI: 10.1007/978-3-030-11123-6_11
https://www.researchgate.net/publication/332598629...

N

Nahum M.P., Gdal-On M., Kuten A., Herzl G., Horovitz Y., Weyl Ben Arush M. Long-term follow-up of children with retinoblastoma. Pediatr Hematol Oncol. 2001 Apr-May;18(3):173-9.
doi: 10.1080/08880010151114769
https://pubmed.ncbi.nlm.nih.gov/11293284/

Narang S., Mashayekhi A., Rudich D., Shields C.L. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clinical & Experimental Ophthalmology.2012. 40:736–42.
DOI: 10.1111/j.1442-9071.2012.02757.x
https://www.ncbi.nlm.nih.gov/pubmed/22300311

Naseripour М. "Retinoblastoma survival disparity": The expanding horizon in developing countries. Saudi J Ophthalmol 2012; 26(2):157–61.
doi: 10.1016/j.sjopt.2012.02.003.
https://pubmed.ncbi.nlm.nih.gov/23960987/

Naseripour М., Nazari H., Bakhtiari P. et al. Retinoblastoma in Iran: outcomes in terms of patients' survival and globe survival // British Journal of Ophthalmology. 2009. Vol. 93. P. 28-32.
DOI: 10.1136/bjo.2008.139410
https://www.ncbi.nlm.nih.gov/pubmed/18952647

Nguyen S.M., Sison J., Jones M., Berry J.L., Kim J.W., Murphree A.L., Salinas V., Olch A.J., Chang E.L., Wong K.K. Lens Dose-Response Prediction Modeling and Cataract Incidence in Patients With Retinoblastoma After Lens-Sparing or Whole-Eye Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1143-1150.
DOI: 10.1016/j.ijrobp.2018.12.004
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667833/

Nyawira G., Kahaki K., Kariuki-Wanyoike M. Survival among retinoblastoma patients at the Kenyatta National Hospital, Kenya. J Ophthalmol East Cent South Afr 2013;17(1).

O

Ochicha O., Gwarzo A.K., Gwarzo D. Pediatric malignancies in Kano, Northern Nigeria // World Journal of Pediatrics. 2012. Vol. 8. N 3. P. 235-239.
DOI: 10.1007/s12519-012-0363-3
https://www.ncbi.nlm.nih.gov/pubmed/22886196

Olteanu C., Dimaras H. Enucleation refusal for retinoblastoma: a global study. 2016, Ophthalmic Genet. 37, 137–143.
https://doi.org/10.3109/13816810.2014.937543

Orjuela М.А., Cabrera-Mun L.; Paul L. et al. Risk of Retinoblastoma Is Associated With a Maternal Polymorphism in Dihydrofolatereductase (DHFR) and Prenatal // Cancer. 2012. Dec. 1. P. 5913-5919.
DOI: 10.1002/cncr.27621
https://www.ncbi.nlm.nih.gov/pubmed/22648968

Orjuela M.A., Titievsky L., Liu X. et al. Fruit and vegetable intake during pregnancy and risk for development of sporadic retinoblastoma // Cancer Epidemiology, Biomarkers & Prevention 2005. Vol. 314. P. 1433-1440.
DOI: 10.1158/1055-9965.EPI-04-0427
https://www.ncbi.nlm.nih.gov/pubmed/15941952

P

Paez-Escamilla M., Bagheri N.,Teira L.E., Corrales-Medina F.F., Harbour W. Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma. JAMA Ophthalmol. 2017 Dec 1;135(12):1453-1454.
doi: 10.1001/jamaophthalmol.2017.4603
https://pubmed.ncbi.nlm.nih.gov/29098282/

Palma J., Sasso D., Dufort G., Koop K., Sampor C., Diez B., Richard L., Castillo L., Chantada G. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant. 2012; 47(4): 522-527.
doi: 10.1038/bmt.2011.108

Parareda A. et al. Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study // Acta Ophthalmol. Blackwell Publishing Ltd, 2014. Vol. 92, № 3. P. 209–215.
DOI: 10.1111/aos.12295
https://pubmed.ncbi.nlm.nih.gov/24868582/

Pascual-Pasto G., Bazan-Peregrino M., Olaciregui N.G., Restrepo-Perdomo C.A., Munier F.L., Chantada G.L., etc. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. 2019, Sci. Transl. Med. 11, eaat9321.
https://doi.org/10.1126/scitranslmed.aat9321

Pérez V., Sampor C., Rey G., Parareda-Salles A., Kopp K., Dabezies A.P., Dufort G., Zelter M., López J.P., Urbieta M., Alcalde-Ruiz E., Catala-Mora J., Suñol M., Ossandon D., Fandiño AC., Croxatto J.O., de Dávila MTG, Reaman G., Ravindranath Y., Chantada GL. Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. JAMA Ophthalmol. 2018 Jul 1;136(7):747-752.
DOI: 10.1001/jamaophthalmol.2018.1501
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136048/

Peterson E.C., Elhammady M.S., Quintero-Wolfe S., Murray T.G., Aziz-Sultan M.A. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: Initial experience with 17 tumors. Journal of Neurosurgery. 2011. 114:1603-8.
DOI: 10.3171/2011.1.JNS10466
https://www.ncbi.nlm.nih.gov/pubmed/21294621

Peylan-Ramu N., Bin-Nun A., Skleir-Levy M., Bibas A., Koplewitz B., Anteby I., Pe'er J. Orbital growth retardation in retinoblastoma survivors: work in progress. Med Pediatr Oncol. 2001 Nov;37(5):465-70.
doi: 10.1002/mpo.1231.
https://pubmed.ncbi.nlm.nih.gov/11745876/

De Potter P. Current treatment of retinoblastoma. Curr Opin Ophthalmol. 2002 Oct;13(5):331-6.
doi: 10.1097/00055735-200210000-00007.
https://pubmed.ncbi.nlm.nih.gov/12218465/

Price E.A., Price K., Kolkiewicz K., etc. Spectrum of RB1 mutations identified in 403 retinoblastoma patients. 2014, J. Med. Genet. 51, 208–214.
https://doi.org/10.1136/jmedgenet-2013-101821

Pritchard E.M., Dyer M.A., Guy R.K. Progress in small molecule therapeutics for the treatment of retinoblastoma. 2016, Mini Rev. Med. Chem. 16, 430–454.
https://doi.org/10.2174/1389557515666150722100610

Q

Qadar L.T., Baqari S.A.S., Maab H., Ali Asghar S., Hafeez M.S. Cureus. Recurrent Sporadic Bilateral Retinoblastoma in a Child with 13q Deletion Syndrome. 2020 Jan 10;12(1):e6618.
DOI: 10.7759/cureus.6618.
https://www.cureus.com/articles/26742-recurrent-sporadic-bilateral-retinoblastoma-in-a-child-with-13q-deletion-syndrome

Qaddoumi I., Bass J.K., Wu J., Billups C.A., Wozniak A.W., Merchant T.E. et al. Carboplatin-associated ototoxicity in children with retinoblastoma. Journal of Clinical Oncology. 2012. 30:1034–41.
DOI: 10.1200/JCO.2011.36.9744
https://www.ncbi.nlm.nih.gov/pubmed/22370329

Quinn C., Tummala R., Anderson J., Dahlheimer T., Nascene D., Jagadeesan B. Effectiveness of alternative routes of intra-arterial chemotherapy administration for retinoblastoma: Potential for response and complications. Interventional Neuroradiology. 2019:1591019919831953.
DOI: 10.1177/1591019919831953.
https://www.ncbi.nlm.nih.gov/pubmed/30931673

R

Radros J., All-Eriksson C., Pal N., Holm S., Seregard S., Söderman M. et al. Intra-arterial chemotherapy for retinoblastoma in Sweden – Evaluation of treatment efficacy and complications. Acta Ophthalmologica.2018; 96:e1040–1.
DOI: 10.1111/aos.13796
https://www.ncbi.nlm.nih.gov/pubmed/29687588

Ramasubramanian A., Kytasty C., Meadows A.T., Shields J.A., Leahey A., Shields C.L. Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era. Am J Ophthalmol 2013;156:825-9.
doi: 10.1016/j.ajo.2013.05.023
https://pubmed.ncbi.nlm.nih.gov/23876864/

Ramasubramanian A., Shields C.L., editors. New Delhi, India: Jaypee Brothers Medical Publishers. 2012. Epidemiology and magnitude of the problem. Retinoblastoma; pp. 10–5.

Ramírez-Ortiz М.A., Ponce-Castaneda M. V., Cabrera-Munoz M.L. et al. Diagnostic Delay and Sociodemographic Predictors of Stage at Diagnosis and Mortality in Unilateral and Bilateral Retinoblastoma // Cancer Epidemiology, Biomarkers & Prevention. 2014. P. 1-9.
DOI: 10.1158/1055-9965.EPI-13-1069
https://cebp.aacrjournals.org/content/23/5/784.long

Rao R., Honavar S.G. Retinoblastoma // Indian Journal of Pediatrics. Springer, 2017. Vol. 84, № 12. P. 937–944.
DOI: 10.1007/s12098-017-2395-0
https://pubmed.ncbi.nlm.nih.gov/28620731/

Rark S.J., Woo S.J., Rark K.H. Incidence of retinoblastoma and survival rate of retinoblastoma patients in Korea using the Korean national cancer registry database (1993-2010) // Investigative Ophthalmology & Visual Science. 2014. Vol. 55. N 5. P. 2816-2821.
DOI: 10.1167/iovs.14-14078.
https://iovs.arvojournals.org/article.aspx?articleid=2127931

Razek A.A., Elkhamary S. MRI of retinoblastoma // British Journal of Radiology. 2011. Vol. 84. P. 775-784.
DOI: 10.1259/bjr/32022497.
https://www.ncbi.nlm.nih.gov/pubmed/21849363

Reddy M.A., Naeem Z., Duncan C., Robertson F., Herod J., Rennie A. et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. British Journal of Ophthalmology. 2017; 101:1704–8
DOI: 10.1136/bjophthalmol-2017-310294.
https://www.ncbi.nlm.nih.gov/pubmed/28432112

Riva G., Augugliaro M., Piperno G., Ferrari A., Rondi E., Vigorito S., Ciardo D., Orecchia R., Jereczek-Fossa B.A. CyberKnife radiotherapy for orbital metastases: A single-center experience on 24 lesions. Eur J Ophthalmol. 2019 Jan;29(1):61-68. PMID: 29587486.
doi: 10.1177/1120672118761728

Rivas-Perea Р., Baker Е., Hamerly G. et al. Detection of leukocoria using a soft fusion of expert classifiers under non-clinical settings // BMC Ophthalmology. 2014. Vol. 14. P. 110.
DOI: 10.1186/1471-2415-14-110
https://bmcophthalmol.biomedcentral.com/articles/10.1186/1471-2415-14-110

Rocha-Bastos R.A., Araújo J.R., Silva R.S. et al. Retinoblastoma: experience of a referral center in the North Region of Portugal // Clinical Ophthalmology. 2014. N 8. P. 993-997.
DOI: 10.2147/OPTH.S59601
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039395/

Rodjan F., Graaf Pd., Brisse H.J., Verbeke J.I., Sanchez E., Galluzzi P., Göricke S. et al. Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: clinic and radiologic characteristics and survival outcomes. Eur J Cancer. 2013 May;49(8):1939-47.
doi: 10.1016/j.ejca.2013.01.010
https://pubmed.ncbi.nlm.nih.gov/23415887/

Rodriguez A., Zugbi S., Requejo F., Deu A., Sampor C., Sgroi M. et al. Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. Pediatric Blood & Cancer.2018;65:e27385.
DOI: 10.1002/pbc.27385
https://www.ncbi.nlm.nih.gov/pubmed/30105793

Rodriguez-Galindo C. Current understanding in the biology and treatment of retinoblastoma // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2005. Т. 4. № 1. С. 41-53.

Rodriguez-Galindo C. et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin // J. Clin. Oncol. 2003. Vol. 21, № 10. P. 2019–2025.
DOI: 10.1200/JCO.2003.09.103
https://pubmed.ncbi.nlm.nih.gov/12743157/

Rodriguez-Galindo C., Wilson M.W. Retinoblastoma. Springer Science +Business Media, LLC. 2010. P. 156. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2019.
DOI: 10.22608/APO.2018294.
https://www.ncbi.nlm.nih.gov/pubmed/30714357

Ross G., Lipper E.G., Abramson D., Preiser L. The development of young children with retinoblastoma. Arch Pediatr Adolesc Med. 2001 Jan;155(1):80-3.
doi: 10.1001/archpedi.155.1.80
https://pubmed.ncbi.nlm.nih.gov/11177067/

Rothschild P.R., Lévy D., Savignoni A. et al. Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond). 2011;25(12):1555–1561.
DOI: 10.1038/eye.2011.198.
https://pubmed.ncbi.nlm.nih.gov/21921957/

Rushlow D, Piovesan B, Zhang K, et al. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat. 2009; 30(5):842-85119280657
DOI: 10.1002/humu.20940.
https://onlinelibrary.wiley.com/doi/10.1002/humu.20940

Ryoo N-K, Kim J-E, Choung H-K et al. Human papilloma virus in retinoblastoma tissues from Korean patients // Korean Journal of Ophthalmology. 2013. Vol. 27. P. 368-371.
DOI: 10.3341/kjo.2013.27.5.368
https://www.ncbi.nlm.nih.gov/pubmed/24082775

S

Saakyan S.V., Tsygankov А.Y., Zhil'tsova M.G., Tadevosyan S.S., Moiseeva N.I., Karamysheva А.F. Retinoblastoma cell culturing and evaluation of their drug resistance. Bulletin of Experimental Biology and Medicine. 2018. Т. 165. № 1. С. 148-153.

Sarici A., Kizilkilic O., Celkan T., Gode S. Blue toe syndrome as a complication of intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol. 2013 Jun;131(6):801-2.
doi: 10.1001/jamaophthalmol.2013.1458.
https://pubmed.ncbi.nlm.nih.gov/23764710/

Scelfo C., Francis J.H., Khetan V., Jenkins T., Marr B., Abramson D.H. et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol 2017;10:961-7.
doi: 10.18240/ijo.2017.06.20.
https://pubmed.ncbi.nlm.nih.gov/28730089/

Christina Scelof, Jasmine H Francis, Vikas Khetan, Thomas Jenkins , Brian Marr, David H Abramson, Carol L Shields, Jacob Pe'er, Francis Munier, Jesse Berry, J. William Harbour, Andrey Yarovoy, Evandro Lucena, Timothy G Murray, Pooja Bhagia, Evelyn Paysse, Samuray Tuncer, Guillermo L Chantada, Annette C Moll, Tatiana Ushakova, David A Plager, Islamov Ziyovuddin, Carlos A Leal, Miguel A Materin, Xun-Da Ji, Jose W Cursino, Rodrigo Polania, Hayyam Kiratli, Charlotta All-Ericsson, Rejin Kebudi, Santosh G Honavar, Vicktoria Vishnevskia-Dai, Sidnel Epelman, Anthony B Daniels, Jeanie D Ling, Fousseyni Traore, Marco A Ramirez-Ortiz. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol 2017; 10(6):961-967

Schaiquevich P., Ceciliano A., Millan N., Taich P., Villasante F., Fandino A.C., Dominguez J., Chantada G.L. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013 May;60(5):766-70. Epub 2012 Sep 28.
doi: 10.1002/pbc.24356.
https://pubmed.ncbi.nlm.nih.gov/23024125/

Schaiquevich P., Fabius A.W., Francis J.H., Chantada G.L., Abramson D.H. Ocular pharmacology of chemotherapy for retinoblastoma.Retina.2017. 37:1–10.
DOI: 10.1097/IAE.0000000000001275.
https://www.ncbi.nlm.nih.gov/pubmed/27617542

Schefler A.C., Braich P.S. Local chemotherapy. In: Ramasubramanian A, Shields C.L., editors.Retinoblastoma.New Delhi, India: Jaypee Brothers Medical Publishers. 2012. pp. 99-108.

Schefler A.C., Kim R.S. Recent advancements in the management of retinoblastoma and uveal melanoma. F1000Res 2018; 7:F1000 Faculty Rev-476.
doi: 10.12688/f1000research.11941.1
https://pubmed.ncbi.nlm.nih.gov/29755733/

Schlienger P., Campana F., Vilcoq J.R., Asselain B. et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol. 2004 Aug;27(4):411-9.
doi: 10.1097/01.coc.0000128861.46357.ee

Schlueter S., Metz K., Bornfeld N., Göricke S., Schlamann M., Sirin S., Biewald E.. Intraokulare Raumforderungen im Kindesalter ohne Retinoblastom [Intraocular Tumors other than Retinoblastoma in Children]. Klin Monbl Augenheilkd. 2015 Jul;232(7):838-44. German.
doi: 10.1055/s-0041-102899.
https://pubmed.ncbi.nlm.nih.gov/26193116/

Schouten-van Meeteren A.Y.N. et al. Chemotherapy for retinoblastoma: An expanding area of clinical research // Medical and Pediatric Oncology. 2002. Vol. 38, № 6. P. 428–438.
DOI:10.1002/mpo.1358
https://onlinelibrary.wiley.com/doi/abs/10.1002/mpo.1358

Schouten-van Meeteren A.Y. et al. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. // Cancer. 2001. Vol. 92, № 11. P. 2933–2940.
PMID: 11753969
https://pubmed.ncbi.nlm.nih.gov/11753969/

Schueler A.O., Flühs D., Anastassiou G. et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. International Journal of radiation oncology, biology, physics. 2006. 65(4): 1212–21.
DOI: 10.1016/j.ijrobp.2006.02.002
https://www.ncbi.nlm.nih.gov/pubmed/16682139

Schueler A.O., Flühs D., Anastassiou G., Jurklies C., Sauerwein W., Bornfeld N. Beta-Ray Brachytherapy of Retinoblastoma: Feasibility of a New Small-Sized Ruthenium-106 Plaque. Ophthalmic Res 2006; 38(1):8–12.
doi: 10.1159/000088259
https://pubmed.ncbi.nlm.nih.gov/16166817/

Schueler A.O., Hosten N., Bechrakis N.E. et al. High resolution magnetic resonance imaging of retinoblastoma // British Journal of Ophthalmology. 2003. Vol. 87. P. 330-335.
DOI: 10.1136/bjo.87.3.330
https://www.ncbi.nlm.nih.gov/pubmed/12598449

Schüler A., Weber S., Neuhäuser M. et al. Age at diagnosis of isolated unilateral retinoblastoma does not distinguish patients with and without a constitutional RB1 gene mutation but is influenced by a parent-of-origin effect. Eur J Cancer. 2005;41(5):735-74015763650
DOI: 10.1016/j.ejca.2004.12.022
https://www.ejcancer.com/article/S0959-8049(05)00022-5/fulltext

Schündeln M.M., Hauffa P.K., Bauer J.J., Temming P., Sauerwein W., Biewald E., Bornfeld N., Hauffa B.P., Grasemann C. Pediatric Survivors of Retinoblastoma Are at Risk for Altered Bone Metabolism After Chemotherapy Treatment Early in Life. Pediatr Hematol Oncol. 2015;32(7):455-66.
doi: 10.3109/08880018.2015.1048912.
https://pubmed.ncbi.nlm.nih.gov/26237585/

Sedghizadeh P.P., Angiero F., Allen C.M., Kalmar J.R., Rawal Y., Albright E.A. Post-irradiation leiomyosarcoma of the maxilla: report of a case in a patient with prior radiation treatment for retinoblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jun;97(6):726-31.
doi: 10.1016/j.tripleo.2003.11.017.
https://pubmed.ncbi.nlm.nih.gov/15184855/

Seregard S., Lundell G., Svedberg H., Kivelä T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology. 2004; 111(6):1228-123215177976
https://www.aaojournal.org/article/S0161-6420(04)00138-1/fulltext

Seregard S., Singh A.D. Retinoblastoma: Direct chemotherapeutic drug delivery into the vitreous cavity. British Journal of Ophthalmology.2012. 96:473-4.
DOI: 10.1136/bjophthalmol-2012-301528.
https://bjo.bmj.com/content/96/4/473

Seth R., Singh A., Guru V., Chawla B., Pathy S., Sapra S. Long-term follow-up of retinoblastoma survivors: Experience from India. South Asian J Cancer. 2017 Oct-Dec;6(4):176-179.
doi: 10.4103/sajc.sajc_179_16
https://pubmed.ncbi.nlm.nih.gov/29404299/

Shah C., Hughes M., Kirzhner M. Anophthalmic syndrome: A review of management // Ophthal. Plast. Reconstr. Surg. 2014. № 5. P. 361–365.
DOI:10.1097/ IOP.0000000000000217

Shah S., Shields C., Lally S., Shields J. Hydroxyapatite orbital implant in children following enucleation: analysis of 531 sockets // Ophthal. Plast. Reconstr. Surg. 2015. № 31. Р. 108-114.
Shahsavari M., Mashayekhi A. Pharmacotherapy for retinoblastoma. // J. Ophthalmic Vis.Res. 2009. Vol. 4, № 3. P. 169–173.
PMID: 23198068; PMCID: PMC3498564.
https://pubmed.ncbi.nlm.nih.gov/23198068/

Shah V., Yadav L., Singh M., Kharbanda S. Custom ocular prosthesis in rehabilitation of a child operated for retinoblastoma. Natl J Maxillofac Surg. 2015 Jul-Dec;6(2):232-6.
doi: 10.4103/0975-5950.183871.
https://pubmed.ncbi.nlm.nih.gov/27390504/

Shanmugan М.Р., Biswas J., Gopal L. et al. The clinical spectrum and treatment outcome of retinoblastoma in Indian children // Journal of Pediatric Ophthalmology and Strabismus. 2005. Vol. 42. P. 75-81.
https://www.ncbi.nlm.nih.gov/pubmed/15825743

Shetty O.A., Naresh K.N., Banavali S.D. et al. Evidence for the presence of high risk human papillomavirus in retinoblastoma tissue from nonfamilial retinoblastoma in developing countries // Pediatric Blood & Cancer.2012. Vol. 58. P. 185-190.
DOI: 10.1002/pbc.23346.
https://www.ncbi.nlm.nih.gov/pubmed/22021092

Shields C.L. EDI-OCT of Intraocular Tumors // Retina Today. Nov/Dec, 2013. P. 62-65.
http://retinatoday.com/pdfs/1113RT_F5_Shields.pdf

Shields C.L., Alset A.E., Say E.A., Caywood E., Jabbour P., Shields J.A. Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. Journal of Pediatric Ophthalmology and Strabismus. 2016. 53. 275–84.
DOI: 10.3928/01913913-20160719-04.
https://www.ncbi.nlm.nih.gov/pubmed/27486728

Shields C.L., Bianciotto C.G., Jabbour P. et al. Intra-arterial chemotherapy for retinoblastoma: report № 2, treatment complications. Archives of Ophthalmology. 2011; 129(11): 1407-1415.
DOI: 10.1001 /archophthalmol. 2011. 151.
https://www.ncbi.nlm.nih.gov/pubmed/21670326

Shields C.L., Bianciotto C.G., Jabbour P., Ramasubramanian A., Lally S.E., Griffin G.C. et al. Intra-arterial chemotherapy for retinoblastoma: Report No 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Archives of Ophthalmology. 2011. 129 1399-406.
DOI: 10.1001/archophthalmol.2011.150.
https://www.ncbi.nlm.nih.gov/pubmed/21670328

Shields C.L., Douglass A.M., Beggache M. et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture. Retina2016;36:1184–1190/
doi: 10.1097/IAE.0000000000000903.
https://insights.ovid.com/article/00006982-201606000-00019

Shields C.L., Fulco E.M., Arias J.D. et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy // Eye (London). 2013. Vol. 27. N 2. P. 253-64.
DOI: 10.1038/eye.2012.175
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574237/

Shields C.L., Honavar S.G., Shields J.A., Demirci H., Meadows A.T., Naduvilath T.J. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120(4):460–4. PMID: 11934319.
https://pubmed.ncbi.nlm.nih.gov/11934319/

Shields C.L., Jorge R., Say E.A., Magrath G., Alset A., Caywood E., Leahey A.M., Jabbour P., Shields J.A. Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia Pac J Ophthalmol (Phila). 2016 Mar-Apr;5(2):97-103.
doi: 10.1097/APO.0000000000000172.
https://pubmed.ncbi.nlm.nih.gov/26765038/

Shields C.L., Kaliki S., Al-Dahmash S., Rojanaporn D., Leahey A., Griffin G. et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation.Retina.2013; 33:2103–9
DOI: 10.1097/IAE.0b013e318295f783.
https://www.ncbi.nlm.nih.gov/pubmed/23873161

Shields C.L., Kaliki S., Rojanaporn D., Al-Dahmash S., Bianciotto C.G., Shields J.A. Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned. Curr Opin Ophthalmol 2012;23(3):202–9.
doi: 10.1097/ICU.0b013e3283524130
https://pubmed.ncbi.nlm.nih.gov/22450222/

Shields C.L., Kaliki S., Shah S.U. et al. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology. 2012;119(1):188-192. tha.2011.06.036.
DOI: 10.1016/j.ophtha.2011.06.036.
https://www.ncbi.nlm.nih.gov/pubmed/21975042

Shields C.L., Lally S.E., Leahey A.M., Jabbour P.M., Caywood E.H., Schwendeman R., Shields J.A. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014 Sep;25(5):374-85.
doi: 10.1097/ICU.0000000000000091.
https://pubmed.ncbi.nlm.nih.gov/25014750/

Shields C.L., Manjandavida F.P., Arepalli S., Kaliki S., Lally S.E., Shields J.A. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmology. 2014. 132.319-25.
DOI: 10.1001/jamaophthalmol.2013.7666.
https://www.ncbi.nlm.nih.gov/pubmed/24407202

Shields C.L., Manjandavida F.P., Pieretti G., Arepalli S.A., Jabbour P., Shields J.A. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014. 121:1453-6.
DOI: 10.1016/j.ophtha.2014.01.026.
https://www.ncbi.nlm.nih.gov/pubmed/24656794

Shields С.L., Mashayekhi A., Au A.K. et al. The International Classification of Retinoblastoma Predicts Chemoreduction Success // Ophthalmology. 2006. Vol. 113. P. 2276-2280.
DOI: 10.1016/j.ophtha.2006.06.018
https://www.ncbi.nlm.nih.gov/pubmed/16996605

Shields C.L., Mashayekhi A., Demirci H. et al. Practical approach to management of retinoblastoma. Archives of Ophthalmology. 2004; 122(5): 729-735.
DOI: 10.1001/ archopht.122.5.729.
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/416286

Shields C.L., Mashayekhi A., Sun H., Uysal Y., Friere J., Komarnicky L., Shields J.A. Iodine 125 Plaque Radiotherapy as Salvage Treatment for Retinoblastoma Recurrence after Chemoreduction in 84 Tumors. Ophthalmology 2006; 113(11):2087–92.
doi: 10.1016/j. ophtha.2006.04.032
https://pubmed.ncbi.nlm.nih.gov/16949158/

Shields C.L., Meadows A.T., Shields J.A., Carvalho C., Smith A.F. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Archives of Ophthalmology.2001. 119:1269–72.
DOI: 10.1001/archopht.119.9.1269
https://www.ncbi.nlm.nih.gov/pubmed/11545631

Shields C.L., Meadows A.T., Leahey A.M., Shields J.A. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004 Dec;24(6):849-62.
doi: 10.1097/00006982-200412000-00003.
https://pubmed.ncbi.nlm.nih.gov/15579981/

Shields С.L., Palamar M., Sharma P.et al. Retinoblastoma Regression Patterns Following Chemoreduction and Adjuvant Therapy in 557 Tumors // Archieves of Ophthalmology. 2009. Vol. 127. N 3. P. 282-290.
DOI: 10.1001/archophthalmol.2008.626.
https://www.ncbi.nlm.nih.gov/pubmed/19273791

Shields C.L., Ramasubramanian A., Thangappan A., Hartzell K., Leahey A., Meadows A.T. et al. Chemoreduction for group E retinoblastoma: Comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology. 2009. 116:544–51.e1
DOI: 10.1016/j.ophtha.2008.10.014.
https://www.ncbi.nlm.nih.gov/pubmed/19157557

Shields C.L., Say E.A.T., Pefkianaki M., Regillo C.D., Caywood E.H., Jabbour P.M. et al. Rhegmatogenous retinal detachment after intraarterial chemotherapy for retinoblastoma: The 2016 founders award lecture. Retina 2017;37:1441-50.
doi: 10.1097/IAE.0000000000001382.
https://pubmed.ncbi.nlm.nih.gov/27787452/

Shields C.L., Say E.A., Pointdujour-Lim R., Cao C., Jabbour P.M., Shields J.A. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol 2015;38(6):542–9. doi: 10.1016/j.jfo.2015.03.004
https://pubmed.ncbi.nlm.nih.gov/25982423/

Shields C.L., Shelil A., Cater J. et al. Development of new retinoblastoma as after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Archives of Ophthalmology. 2003;121(11):1571-1576
DOI: 10.1001/archopht.121.11.1571.
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/415842

Shields C.L., Shields J.A. Diagnosis and management of retinoblastoma // Cancer Control. 2004. Vol. 11. N 5. Р. 317-327.
DOI: 10.1177/107327480401100506
https://www.ncbi.nlm.nih.gov/pubmed/15377991

Shields C.L., Shields J.A. Intra-arterial chemotherapy for retinoblastoma: The beginning of a long journey // Clinical and Experimental Ophthalmology. 2010. Vol. 38, № 6. P. 638–643.
DOI: 10.1111/j.1442-9071.2010.02297.x
https://pubmed.ncbi.nlm.nih.gov/20584015/

Shields C.L., Shields J.A. Intra-arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2016 Oct 1;134(10):1201.
doi: 10.1001/jamaophthalmol.2016.2712.
https://pubmed.ncbi.nlm.nih.gov/27533705/

Shields C.L., Shields J.A. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010 May;21(3):203-12.
doi: 10.1097/ICU.0b013e328338676a.
https://pubmed.ncbi.nlm.nih.gov/20224400/

Shields C.L., Shields J.A., Cater J., Othmane I., Singh A.D., Micaily B. Plaque radiotherapy for retinoblastoma. Long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001;108(11):2116–21.
doi: 10.1016/s0161-6420(01)00797-7
https://pubmed.ncbi.nlm.nih.gov/11713089/

Shields C.L., Shields J.A., Lally S.E., Eagle RC. Jr. Harvesting fresh tumor tissue from enucleated eyes: the 2008 Jack S. Guyton lecture. Arch Ophthalmol. 2010;128(2):241-24320142549
DOI: 10.1001/archophthalmol.2009.396
https://jamanetwork.com/journals/jamaophthalmology...

Shields C.L., Shields J.A. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999 Jan-Feb;36(1):8-18; quiz 35-6. PMID: 9972509.
doi: 10.3928/0191-3913-19990101-04

Shields C.L., Uysal Y., Marr B.P., Lally S.E., Rodriques E., Kharod B., Shields J.A. Experience with the polymer-coated hydroxyapatite implant after enucleation in 126 patients. Ophthalmology. 2007 Feb;114(2):367-73.
doi: 10.1016/j.ophtha.2006.08.030.
https://pubmed.ncbi.nlm.nih.gov/17270685/

Shields J., Shields C. Retinoblastoma: introduction, genetics, clinical features, classification // Shields J., Shields C., Eds. Atlas of Intraocular Tumors, 3rd ed., Philadelphia: Lippinocott, Wolters Kluwer; 2016. p. 311-314

Shildkrot Y., Kirzhner M., Haik B.G., Qaddoumi I., Rodriguez-Galindo C., Wilson M.W. The effect of cancer therapies on pediatric anophthalmic sockets // Ophthalmology. 2011. № 12. P. 2480–2486.
DOI: 10.1016/j.ophtha.2011.05.024

Shimoda Y., Hamano R., Ishihara K., Shimoda N., Hagimura N., Akiyama H., Kishi S., Kaneko A. Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):501-8. Epub 2007 Oct 13.
doi: 10.1007/s00417-007-0685-3.
https://pubmed.ncbi.nlm.nih.gov/17934752/

Simpson E.R., Gallie B., Laperrierre N., Beiki-Ardakani A., Kivelä T. et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13(1):1–14.
doi: 10.1016/j.brachy.2013.11.008
https://pubmed.ncbi.nlm.nih.gov/24373763/

Singh H.P., Wang S., Stachelek K., Lee S. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. 2018, Proc. Natl. Acad. Sci. U. S. A. 115, E9391–E9400.
https://doi.org/10.1073/pnas.1808903115

Sirin S., de Jong M.C., de Graaf P., Brisse H.J., Galluzzi P., Maeder P., Bornfeld N., Biewald E., Metz K.A., Temming P., Castelijns J.A., Goericke S.L.; European Retinoblastoma Imaging Collaboration. High-Resolution Magnetic Resonance Imaging Can Reliably Detect Orbital Tumor Recurrence after Enucleation in Children with Retinoblastoma. Ophthalmology. 2016 Mar;123(3):635-45.
DOI: 10.1016/j.ophtha.2015.10.054.

Sirin S., Schlamann M., Metz K.A., Bornfeld N., Schweiger B., Holdt M., Temming P., Schuendeln M.M., Goericke S.L. High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: MRI vs. histopathology. Neuroradiology. 2015 Aug;57(8):805-14.
DOI: 10.1007/s00234-015-1544-2.
https://www.ncbi.nlm.nih.gov/pubmed/26041632

Sirin S., Schlamann M., Metz K.A., Bornfeld N., Schweiger B., Holdt M., Temming P., Schuendeln M.M., Goericke S.L. High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: new vs. old imaging concept. Neuroradiology. 2015 Aug;57(8):805-14.
DOI: 10.1007/s00234-015-1538-0.
https://www.ncbi.nlm.nih.gov/pubmed/25964026

Sivakumaran T.A., Ghose S., Kumar H., Kucheria K. Parental age in Indian patients with sporadic hereditary retinoblastoma // Ophthalmic Epidemiology. 2000. N 7. P. 285-291.
DOI: 10.1076/opep.7.4.285.4172
https://www.ncbi.nlm.nih.gov/pubmed/11262675

Skalet A.H., Gombos D.S., Gallie B.L., Kim J.W., Shields C.L., Marr B.P., Plon S.E., Chévez-Barrios P. Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018 Mar;125(3):453-458.
DOI: 10.1016/j.ophtha.2017.09.001
https://www.aaojournal.org/article/S0161-6420(17)31784-0/references

Smith S.J., Pulido J.S., Salomão D.R., Smith B.D., Mohney B. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. British Journal of Ophthalmology.2012. 96:1073-7.
DOI: 10.1136/bjophthalmol-2011-300829.
https://www.ncbi.nlm.nih.gov/pubmed/22368261

Smith S.J., Smith B.D. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013.
DOI:10.1136/bjophthalmol-2013-303188
https://bjo.bmj.com/content/97/10/1231

Smith S.J., Smith B.D., Mohney B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. British Journal of Ophthalmology. 2014. 98. 292-7.
DOI: 10.1136/bjophthalmol-2013-303885.
https://www.ncbi.nlm.nih.gov/pubmed/24187047

Sohajda Z., Damjanovich J., Bárdi E., Szegedi I., Berta A., Kiss C. Combined Local Treatment and Chemotherapy in the Management of Bilateral Retinoblastomas in Hungary. J Pediatr Hematol Oncol 2006; 28(6):399–401.
doi: 10.1097/00043426-200606000-00016
https://pubmed.ncbi.nlm.nih.gov/16794512/

Soliman S.E., Racher H., Zhang C., MacDonald H., Gallie B.L., 2017. Genetics and molecular diagnostics in retinoblastoma–an update. Asia Pac J Ophthalmol (Phila) 6, 197–207.
https://doi.org/10.22608/APO.201711

Soliman S.E., VandenHoven C., Mackeen L.D., Gallie B.L. Vision and visual potential for perifoveal retinoblastoma after optical coherence tomographic-guided sequential laser photocoagulation. Br J Ophthalmol. 2019 Jun;103(6):753-760.
DOI: 10.1136/bjophthalmol-2018-312125
https://www.ncbi.nlm.nih.gov/pubmed/29976784

Soliman S.E., VandenHoven C., Mackeen L.D., Heon E., Gallie B.L. Optical Coherence Tomography-Guided Decisions in Retinoblastoma Management. Ophthalmology. 2017 Jun;124(6):859-872.
DOI: 10.1016/j.ophtha.2017.01.052
Stannard C., Sauerwein W., Maree G., Lecuona K. Radiotherapy for ocular tumours. Eye 2013; 27(2):119–27.
doi: 10.1038/eye.2012.241
https://pubmed.ncbi.nlm.nih.gov/23174750/

Stenzel E., Göricke S., Temming P., Biewald E., Zülow S., Göbel J. et al. Feasibility of intra-arterial chemotherapy for retinoblastoma: Experiences in a large single center cohort study. Neuroradiology.2019.61:351–7.
DOI: 10.1007/s00234-019-02153-9.
https://www.ncbi.nlm.nih.gov/pubmed/30643921

Sullivan E.M., Wilson M.W., Billups C.A., et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014; 36(6):e335-e340.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41085...

Sultan I., Hajja Y., Nawaiseh I., Mehyar M., Deebajah R., Jaradat I., Yousef Y.A. Chemoreduction of Progressive Intraocular Retinoblastoma by Systemic Topotecan. Ophthalmic Genet 2016;37(2):209–13.
doi: 10.3109/13816810.2015.1039138.
https://pubmed.ncbi.nlm.nih.gov/26760494/

Suzuki S., Aihara Y., Fujiwara M., Sano S., Kaneko A. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol. 2015 May;59(3):164-72.
doi: 10.1007/s10384-015-0378-0.
https://pubmed.ncbi.nlm.nih.gov/25808017/

Suzuki S., Yamane T., Mohri M., Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011; 118(10): 2081-2087.
DOI: 10.1016/j.ophtha.2011.03.013
https://www.ncbi.nlm.nih.gov/pubmed/21715012

T

Taich P., Ceciliano A., Buitrago E., Sampor C., Fandino A., Villasante F. et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology. 2014; 121:889-97.
DOI: 10.1016/j.ophtha.2013.10.045.
https://www.ncbi.nlm.nih.gov/pubmed/24359624

Tamboli D., Topham A., Singh N., Singh A.D. Retinoblastoma: A SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms. Am. J. Ophthalmol. 2015; 160 (5): 953–8.
doi: 10.1016/j.ajo.2015.07.037
https://www.ajo.com/article/S0002-9394(15)00461-4/fulltext

Temming P., Arendt M., Viehmann A., Eisele L. et al. How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol. 2016 Sep 10;34(26):3183-8.
doi: 10.1200/JCO.2015.65.4012.
https://pubmed.ncbi.nlm.nih.gov/27382102/

Temming P., Arendt M., Viehmann A., Eisele L., Le Guin C.H., Schündeln M.M., Biewald E., Astrahantseff K., Wieland R., Bornfeld N., Sauerwein W., Eggert A., Jöckel K.H., Lohmann D.R. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer. 2017 Jan;64(1):71-80.
DOI: 10.1002/pbc.26193.
https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.26193

TNM: Классификация злокачественных опухолей / Перевод изд. TNM Classification of Malignant Tumours, 81*1 ed. Под ред. Дж.Д. Брайерли и др.; пер. с англ. и научн. ред. Е.А. Дубовой, К.А. Павлова. 2-е изд. на русском языке. М.: Логосфера, 2018.

Tse B.C., Steinle J.J., Johnson D., Haik B.G., Wilson M.W. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: Histopathologic findings.JAMA Ophthalmology.2013;131:903-1.
DOI: 10.1001/jamaophthalmol.2013.2065.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251809/

Tuncer S., Sencer S., Kebudi R., Tanyıldız B., Cebeci Z., Aydın K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: First 4-year experience from a single institution in Turkey. Acta Ophthalmologica.2016;94:e644-651.
DOI: 10.1111/aos.13077.
https://www.ncbi.nlm.nih.gov/pubmed/27214798

Turaka K., Shields C.L., Meadows A.T., Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatric Blood & Cancer. 2012;59(1):121-125.
DOI: 10.1002/ pbc.23278.
https://www.ncbi.nlm.nih.gov/pubmed/2182678

U

Usmanov R., Rustam H., Kivelä T. Predicted Trends in the Incidence of Retinoblastoma in the Asia-Pacific Region // The Asia-Pacific Journal of Ophthalmology. 2014. Vol. 3. N 3. P. 151-157.
DOI: 10.1097/APO.0000000000000060
https://www.ncbi.nlm.nih.gov/pubmed/26107585

Uusitalo M.S., Van Quill K.R., Scott I.U., Matthay K.K., Murray T.G., O'Brien J.M. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001 Jan;119(1):41-8. PMID: 11146725.
https://pubmed.ncbi.nlm.nih.gov/11146725/

V

Vajzovic L.M., Murray T.G., Aziz-Sultan M.A., Schefler A.C. et al. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol. 2010 Dec;128(12):1619-23.
doi: 10.1001/archophthalmol.2010.296
https://pubmed.ncbi.nlm.nih.gov/21149791/

Vajzovic L.M., Murray T.G., Aziz-Sultan M.A., Schefler A.C., Wolfe S.Q., Hess D. et al. Supraselective intra-arterial chemotherapy: Evaluation of treatment-related complications in advanced retinoblastoma. Clinical Ophthalmology. 2011. 5:171-6.
DOI: 10.2147/OPTH.S12665
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045066/

van Dijk J., Huisman J., Moll A.C., Schouten-van Meeteren A.Y. et al. Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes. 2007 Dec 3;5:65. doi: 10.1186/1477-7525-5-65.
PMID: 18053178;
PMCID: PMC2219958.

van Dijk J., Imhof S.M., Moll A.C., Ringens P.J. et al. Quality of life of adult retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes. 2007 Jun 4;5:30.
doi: 10.1186/1477-7525-5-30.
https://pubmed.ncbi.nlm.nih.gov/17547767/

Venturi C., Bracco S., Cerase A., Cioni S., Galluzzi P., Gennari P. et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: Preliminary results from 140 treatments. Acta Ophthalmologica. 2013. 91:335-42
DOI: 10.4103/ijo.IJO_866_19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552585/

W

Wang L., Wang C., Wu T., Sun F. Long non-coding RNA TP73-AS1 promotes TFAP2B-mediated proliferation, metastasis and invasion in retinoblastoma via decoying of miRNA-874-3p. Journal of Cell Communication and Signaling. Feb-2020.
DOI: 10.1007/s12079-020-00550-x

Wenzel C.T., Halperin E.C., Fisher S.R. Second malignant neoplasms of the head and neck in survivors of retinoblastoma. Ear Nose Throat J. 2001 Feb;80(2):106, 109-12. PMID: 11233341
https://pubmed.ncbi.nlm.nih.gov/11233341/

Williams C.L., Bunch K.J., Stiller C.A., Murphy M.F., Botting B.J., Wallace W.H., Davies M., Sutcliffe A.G. Cancer risk among children born after assisted conception. New Engl J Med. 2013; 369(19):1819–1827.
DOI: 10.1056/NEJMoa1301675
https://www.ncbi.nlm.nih.gov/pubmed/24195549

Wilson M.W., Qaddoumi I., Billups C., Haik B.G., Rodriguez-Galindo C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. The British journal of ophthalmology. 2011. 95:553–8.
DOI: 10.1136/bjo.2009.177444
https://www.ncbi.nlm.nih.gov/pubmed/20693555

Wilson M.W., Steinle J.J., Johnson D.A. Ocular Pathology: Essential for defining and refining the treatment of Retinoblastoma // International Journal of Ophthalmology. Pathology. 2012. 1:1.
DOI:10.4172/2324-8599.1000e103
https://www.scitechnol.com/peer-review/ocular-pathology-essential-for-defining-and-refining-the-treatment-of-retinoblastoma-Beks.php?article_id=106

Wladis E.J., Aakalu V.K., Sobel R.K., Yen M.T., Bilyk J.R., Mawn L.A. Orbital Implants in Enucleation Surgery // Ophthalmology. 2018. № 2. P. 311-317.
DOI: 10.1016/j.ophtha.2017.08.006

Wong J.R., Morton L.M., Tucker M.A., Abramson D.H., Seddon J.M., Sampson J.N., Kleinerman R.A. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014 Oct 10;32(29):3284-90.
doi: 10.1200/JCO.2013.54.7844.
https://pubmed.ncbi.nlm.nih.gov/25185089/

Wong J.R., Tucker M.A., Kleinerman R.A., Devesa S.S. Retinoblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program // JAMA Ophthalmology. 2014. Vol. 132. N 4. P. 478-483.
DOI: 10.1001/jamaophthalmol.2013.8001.
https://www.ncbi.nlm.nih.gov/pubmed/24577366

Х

Xue K., Ren H., Meng F., Zhang R., Qian J. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. BMC Ophthalmol. 2019 Feb 26;19(1):61.
doi: 10.1186/s12886-019-1059-4.
https://pubmed.ncbi.nlm.nih.gov/30808420/

Xu X.L., Fang Y., Lee T.C., Abramson D.H., etc. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. 2009, Cell 137, 1018–1031.
https://doi.org/10.1016/j.cell.2009.03.051

Xu X.L., Singh H.P., Wang L., Abramson, D.H., etc. Rb suppresses human cone-precursor-derived retinoblastoma tumours. 2014. Nature 514, 385–388.
https://doi.org/10.1038/nature13813


Y

Yamanaka R., Hayano A., Takashima Y. Trilateral retinoblastoma: A systematic review of 211 cases. Neurosurg Rev. 2019; 42(1):39-48.
doi: 10.1007/s10143-017-0890-4

Yamane T., Kaneko A., Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. International Journal of Clinical Oncology. 2004. 9(2): 69-73. 0392-6.
DOI: 10.1007/s10147-004-0392-6
https://doi.org/10.1007/s10147-004-0392-6

Yang M., Wei W. Long non-coding RNAs in retinoblastoma. 2019, Pathol. Res. Pract. 215, 152435
https://doi.org/10.1016/j.prp.2019.152435

Yanık Ö., Gündüz K., Yavuz K., Taçyıldız N., Ünal E. Chemotherapy in Retinoblastoma: Current Approaches. Turk J Ophthalmol. 2015 Dec;45(6):259-267. Epub 2015 Dec 5.
doi: 10.4274/tjo.06888.
https://pubmed.ncbi.nlm.nih.gov/27800245/

Yarovoy A.A., Ushakova T.L., Gorshkov I.M., Polyakov V.G., Golubeva O.V., Gorovtsova O.V., Krivovyaz O.S. Intraocular surgery with melphalan irrigation for vitreous hemorrhage in an only eye with retinoblastoma Eur J Ophthalmol. 2015 Dec 1;26(1):e17-9.
DOI: 10.5301/ejo.5000683.

Yousef Y.A., Al-Hussaini M., Mehyar M., Sultan I., etc. Predictive value of TNM classification, international classification, and reese-ellsworth staging of retinoblastoma for the likelihood of high-risk pathologic features. 2015. Retina 35, 1883–1889.
https://doi.org/10.1097/IAE.0000000000000547

Yu C.L., Tucker M.A., Abramson D.H., Furukawa K. et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst. 2009 Apr 15;101(8):581-91.
doi: 10.1093/jnci/djp046.
https://pubmed.ncbi.nlm.nih.gov/19351917/

Yu M.D., Dalvin L.A., Welch R.J., Shields C.L. Precision Intravitreal Chemotherapy for Localized Vitreous Seeding of Retinoblastoma. Ocul Oncol Pathol. 2019 Jun;5(4):284-289. Epub 2018 Sep 13.
doi: 10.1159/000491432.
https://pubmed.ncbi.nlm.nih.gov/31367592/

Z

Zhang J., Benavente C., McEvoy J., etc. A novel retinoblastoma therapy from genomic and epigenetic analyses. 2012, Nature 481, 329–334 (2012).
https://doi.org/10.1038/nature10733

Zhang L., Gao T., Shen Y. Quality of life in children with retinoblastoma after enucleation in China. Pediatric Blood & Cancer. 2018. Vol. 65, №7. e27024
https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.27024

Zhao J., Dimaras H., Massey C., Xu X., Huang D., Li B. et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. Journal of Clinical Oncology.2011. 29:845–51.
DOI: 10.1200/JCO.2010.32.5332
https://www.ncbi.nlm.nih.gov/pubmed/21282531

Zhao J., Li Q., Wu S., Jin L., Ma X., Jin M., Wang Y., Gallie B. Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma. Ophthalmology. 2018 Feb;125(2):320-322.
DOI: 10.1016/j.ophtha.2017.10.015
https://www.aaojournal.org/article/S0161-6420(17)32965-2/fulltext

Zigiotti G.L., Cavarretta S., Morara M. et al.: Standard enucleation with aluminium oxide implant (bioceramic) covered with patient's sclera. Scientific World Journal. 2012, 2012:481584.
DOI:10.1100/2012/481584
https://www.hindawi.com/journals/tswj/2012/481584/